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 The hepatic acute phase response (APR), stimulated by injury or inflammation, is 
characterized by significant changes in circulating acute phase protein (APP) 
concentrations.  While individual functions of liver-derived APPs are known, the net 
consequence of APP changes is unclear.  Pneumonia and sepsis elicit systemic 
inflammation and induce a robust APR.  Although APR activation is regarded as a 
hallmark of infection, direct contributions of liver activation to pulmonary defense during 
pneumonia and sepsis-induced pneumonia remain unclear.  Pneumonia causes a 
pulmonary inflammatory response coordinated largely by alveolar macrophages, and is 
typified by cytokine production, leukocyte recruitment and plasma extravasation, the 
latter of can enable delivery of hepatocyte-derived APPs to the infection site.  To 
determine the functional significance of the hepatic APR during pneumonia, we 
challenged APR-null mice lacking hepatocyte signal transducer and activator of 
transcription-3 (STAT3) and RelA with 106 colony-forming units (CFU) Escherichia coli 
intratracheally.  HepSTAT3/RelA-/- mice displayed ablated APP induction, significantly 
	  	   x	  
increased mortality, tumor necrosis factor-dependent hepatotoxicity, and pulmonary 
bacterial burdens.  Following a lower (4x105 CFU) E. coli inoculum, hepSTAT3/RelA-/- 
mice had decreased APP concentrations with reduced pulmonary inflammation and 
diminished airspace macrophage activation.  Similar results were obtained in the context 
of endotoxemia and pneumonia.  We employed an endotoxemia/pneumonia model, 
whereby 18 hours of intraperitoneal E. coli lipopolysaccharide (5 mg/kg) was followed 
by intratracheal E. coli (106 CFU) in mice lacking hepatocyte STAT3 (hepSTAT3-/-) or 
control hepSTAT3+/+ mice.  Following endotoxemia and pneumonia, hepSTAT3-/- mice, 
with significantly reduced levels of circulating and airspace APPs, exhibited significantly 
elevated lung and blood bacterial burdens and mortality. While neither recruited airspace 
neutrophils nor lung injury were altered in endotoxemic hepSTAT3-/- mice, in vivo 
production of reactive oxygen species in alveolar macrophage was significantly 
decreased.  Additionally, bronchoalveolar lavage fluid from this group of hepSTAT3-/- 
mice allowed greater bacterial growth ex vivo.  These results identify a lung-liver axis, 
whereby the liver response enhances macrophage activation and pulmonary host defense 
during pneumonia and sepsis-induced pneumonia.  Taken together, induction of liver 
acute phase gene expression programs contributes to countering the deleterious 
consequences of pneumonia, whether it is alone or in the context of sepsis-induced 
infection. 
	  	   xi	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CHAPTER 1: INTRODUCTION 
Pneumonia 
History, Clinical Significance, and Epidemiology 
 Pneumonia has long been appreciated throughout the history of modern culture as 
an acute, but severe illness.  In fact, Dr. William Osler, the father of modern medicine, 
stated that as “the most widespread and fatal of all acute diseases, pneumonia is now the 
‘Captain of Men of Death’” (Osler, 1905).  Before the advent of antibiotics, there was no 
specific treatment recommended.  Dr. Osler wrote that “alcohol may be used with benefit 
in a majority of cases” (Osler, 1905).  Without antibiotics, mortality rates were as high as 
30% in city hospitals (Dowling, 1972).  Mortality rates due to pneumonia have seen some 
important trends throughout the 20th century, with the most notable being the 1918 
influenza epidemic, which quadrupled mortality rates, peaking around 600,000 deaths per 
100,000 people per year.  Interestingly, the majority of these deaths were attributable to 
bacterial superinfections and not the influenza infection itself (Mizgerd, 2012).  It wasn’t 
until the mid 20th century with the advent of antibiotic therapies, that mortality rates 
dropped to around 40 deaths per 100,000 persons per year by 1960 (from around 100 
deaths per 100,000 persons per year in 1940) and have remained relatively unchanged 
since (Armstrong et al., 1999).   
Presently, pneumonia accounts for the greatest global burden of disease, as it is 
responsible for the most disability-adjusted life years (DALYs) lost, a metric put forth by 
the World Health Organization (WHO), than any other disease including diarrheal 
diseases, human immunodeficiency virus/acquired immunodeficiency syndrome and 
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tuberculosis (Mizgerd, 2012).  Within the United States, acute lung infections, including 
both pneumonia and influenza, cause the most infection-related deaths (Mizgerd, 2006), 
and pneumonia itself is responsible for the most childhood hospitalizations  (Yu et al., 
2011).  Overall, there are about 5 million cases of pneumonia each year, with about one 
million patients hospitalized annually due to pneumonia (Eddy, 2009).  Hospitalization 
rates for pneumonia are stratified greatly due to age, with the greatest incidence in the 
elderly and children under two years of age (Griffin et al., 2013).  In fact, in elderly 
adults, age 85 or greater, hospitalization rates due to pneumonia are over 4,000 
hospitalizations per 100,000 persons annually.  This rate is cut in half in adults 74-85 
years old; and for children under two years of age hospitalization rates are just under 
1,000 hospitalizations per 100,000 persons (Griffin et al., 2013). 
Hospital-acquired or nosocomial pneumonia is a major complication in intensive 
care units (ICUs) that is associated with high morbidity and mortality (Lynch, 2001).  
The general incidence of nosocomial pneumonia is 0.5-2.0% of all hospital admissions.  
It is a common hospital-acquired infection (second to urinary tract infections) that has the 
highest associated mortality rate of any nosocomial infection (30-70%) (Blasi, 2010; 
Lynch, 2001; Richards et al., 1999). 
 
Causes of Pneumonia 
 Pneumonia is caused by a multitude of organisms, including bacterial, viral and 
fungal agents (Musher and Thorner, 2014).  The Gram-positive bacterium, Streptococcus 
pneumoniae, remains the number one causative agent of community-acquired pneumonia 
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(Garau and Calbo, 2008).  There are a number of different estimates as to the number of 
cases caused by S. pneumoniae annually, and reports have determined that anywhere 
from 10-15% of inpatient cases (Musher and Thorner, 2014) to 30-50% (Garau and 
Calbo, 2008; Rudan et al., 2008) of all reported cases are due to pneumococcus.  There 
are over 90 immunologically distinct serotypes of pneumococcus, each having a distinct 
composition of the polysaccharide capsule, which results in large differences in virulence 
among serotypes (Hammerschmidt et al., 2005; Hausdorff et al., 2005; Kadioglu et al., 
2008).  Other bacterial species, such as Haemophilus influenza, Staphylococcus aureus, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa and other Gram-negative rods, are 
important, but less frequent causes of community-acquired pneumonia (Garau and Calbo, 
2008; Musher and Thorner, 2014; Rudan et al., 2008).  On the other hand, hospital-
acquired pneumonia is most frequently caused by S. aureas and other Gram-negative 
bacterial species, including P. aeruginosa, K. pneumoniae, E. coli, and other 
enterobacteria (Blasi, 2010; Jones, 2010; Lynch, 2001; Richards et al., 1999). 
It is now becoming more recognized, with the advent of polymerase chain 
reaction (PCR) used as a diagnostic, that various respiratory viruses are also a major 
causative agent for pneumonia (Musher and Thorner, 2014).  Respiratory syncytial virus 
(RSV), parainfluenza virus, influenza, and human metapneumovirus are among some of 
relevant causes of viral pneumonia (Garau and Calbo, 2008; Musher and Thorner, 2014; 
Rudan et al., 2008).  In fact, a recent study has suggested that the incidence of viral 
pneumonia in children is more prevalent that originally thought, with the majority of the 
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cases due to RSV infection.  These studies, however, should be interpreted cautiously 
since they were more empowered to detect viral species (Jain et al., 2015).  
 
Pathology and Immune Response 
 Pneumonia is defined clinically as an acute inflammatory condition in which the 
alveolar space, the site of gas exchange, is filled with fluid and immune cells (Guyton 
and Hall, 2000).  Once in the lower respiratory tract, recognition of pathogens occurs 
through pattern-recognition receptors (PRRs) on sentinel cells within the airspaces, which 
are predominantly alveolar macrophages and epithelial cells (Mizgerd, 2008).  This 
recognition causes an innate immune response that is typified by alveolar inflammation.  
Proinflammatory cytokines and chemokines are produced, and immune cells, particularly 
neutrophils, are recruited to the airspaces, resulting in a hostile environment for microbes 
to survive (Guyton and Hall, 2000; Longo, 2012; Mizgerd, 2008; Society and America, 
2005).  Pathogen killing, however, generally results in acute lung injury (ALI), which 
damages the delicate alveolar epithelium and allows for fluid buildup and plasma protein 
extravasation into the alveolar space (Matthay et al., 2012; Mizgerd, 2008; Ware and 
Matthay, 2000).  Indeed, proteinaceous edema is a hallmark of the acute respiratory 
distress syndrome (ARDS), which is a complex and deadly syndrome most often caused 
by pneumonia (Matthay et al., 2012; Ware and Matthay, 2000).  The specific innate 
immune response and the cell types involved are reviewed later in this dissertation.   
Pneumonia and ARDS are diagnosed by radiographic confirmation, the majority 
of time being X-ray, of fluid buildup within the lungs.  Instead of normal, clear airspaces, 
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cloudy infiltrates can be seen within the pulmonary space (Longo, 2012; Niederman et 
al., 2001; Society and America, 2005).  Patient sputum samples are also cultured and 
Gram-stained to identify the causative bacterial species, or in the case of viral 
pneumonia, subjected to PCR analysis.   
 
Treatment and Vaccines 
Antibiotic therapy is the most common treatment of bacterial pneumonia 
(Niederman et al., 2001).  As a better determinate of the specific antibiotic treatment, 
patient populations are stratified into four groups based on specific risk factors and their 
outpatient or inpatient standing.  Some risk factors include the presence of 
cardiopulmonary diseases like congestive heart failure or chronic obstructive pulmonary 
disease, and the likelihood of developing an antibiotic-resistant infection, which is based 
on modifying factors such as age, alcoholism, residence in a nursing home, and recent 
antibiotic therapy (Niederman et al., 2001).  Recommended antibiotics include advanced 
generation macrolides, doxycycline, β-lactams, and antipneumococcal fluoroquinolones 
given either orally or intravenously, depending on the severity of infection (Niederman et 
al., 2001; Society and America, 2005).  Antibiotic resistance has become an increasing 
concern, especially in hospital-acquired pneumonia (Moroney et al., 2001).  Several risk 
factors, including length of hospital stay, recent antibiotic therapy, and presence of 
immunosuppressive disease, are used to identify patients at risk to develop resistant 
pneumonias.  Of all pneumonia etiologies, P. aeruginosa is most frequently multidrug-
resistant, followed by Klebsiella and Enterobacter and other Gram-negative species 
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(Moroney et al., 2001; Society and America, 2005).  In severe cases of pneumonia, like 
those that progress to ARDS, supportive care and ventilation are necessary in addition to 
antibiotics (Matthay et al., 2012; Ware and Matthay, 2000; Ware and Matthay, 2005).   
Two pneumococcal vaccines are commercially available, both worldwide and in 
the United States: the pneumococcal polysaccharide vaccine (PPSV23 or Pneumovax®) 
and the pneumococcal conjugate vaccine (PCV or Prevnar®).  PPSV23 has been 
commercially available since 1983, and has been shown to reduce the incidence of 
invasive pneumococcal disease, but not pneumonia or pneumonia-related mortality rates 
(Pisano and Cifu, 2015).  The PPSV23 vaccine is a combination of purified 
polysaccharides from the capsules of 23 different serotypes of S. pneumoniae, which 
induce a B-cell-dependent immune response through immunoglobulin M (IgM) (NCIRD, 
2013b; Pisano and Cifu, 2015; Pletz et al., 2008).  Because this vaccine does not 
stimulate a robust response, immunological memory is not induced and boosters are 
needed every 5-6 years (Moberley et al., 2013; Pletz et al., 2008; Rubins et al., 1998).  
Additionally, PPSV23 is not recommended for children under two years of age (NCIRD, 
2013b; Pisano and Cifu, 2015).  The first pneumococcal conjugate vaccine, PCV7 or 
Prevnar7®, was introduced in 2000 and has since been adapted as part of the pediatric 
vaccine schedule (NCIRD, 2013a; Pisano and Cifu, 2015).   PCV7, and its later 
counterpart PCV13, are comprised of capsular polysaccharides from 7 or 13 serotypes, 
respectively, of S. pneumoniae that are conjugated to a diphtheria toxoid protein that is 
highly immunogenic.  By utilizing this protein as an immunomodulator, these vaccines 
are able to induce immune memory and provide lasting protection (Pisano and Cifu, 
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2015; Pletz et al., 2008).  The Centers for Disease Control recommend all children under 
the age of two and adults over 65 receive the PCV13 vaccination (NCIRD, 2013a).  After 
its introduction in 2000, the PCV7 vaccine reduced childhood hospitalization rates by 
~550 per 100,000 children per year and those in elderly adults aged 85 and older by 
~1,300 per 100,000 cases a year.  Even with the advent of the pneumococcal vaccines, 
however, the mortality and morbidity of pneumonia remains significant, as there are still 
high levels of hospitalizations and mortality.  Worldwide, the WHO recommends 
vaccination for all children.  Even so, vaccination rates are low, as only 25% coverage is 
reported globally (Organization, 2014; Organization, 2015). 
While the PCV and PPSV vaccines have reduced disease associated with S. 
pneumoniae, only one other vaccine exists for other bacterial etiologies – Haemophilus 
influenzae type b (Hib).  There are three different Hib vaccines available, and all are 
conjugate vaccines whereby, similar to the PCV, the capsular polysaccharide of Hib 
(PRP) is conjugated to immunogenic protein (Adams et al., 1993).  One vaccine, PRP-D, 
utilizes the Hib PRP polysaccharide protein that is conjugated to a diphtheria toxoid 
conjugate, another similar conjugate used the diphtheria CRM197 protein as the 
conjugate (called HbOC), while the third is conjugated to a meningococcal protein 
(referred to as (PRP-OMP) (Adams et al., 1993).  Besides the conjugate, they differ in the 
size of the polysaccharide used and the method of chemical conjugation.  All three were 
approved by the Food and Drug Administration by 1989 and have been integrated into 
the pediatric vaccination schedule (Adams et al., 1993).  Worldwide the Hib vaccines are 
also recommended for children under five (Organization, 2014).  The WHO reports 
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global vaccination coverage of 52% (Organization, 2015). Currently, there are no other 
vaccinations available for other etiologies.   
 
Sepsis 
Clinical Definition and Significance 
Sepsis, which is tightly linked to pneumonia (more below), is a complex and 
variable syndrome that is defined as a systemic inflammatory response to infection 
(Angus and van der Poll, 2013; Lagu et al., 2012).  Differences in severity delineate the 
syndrome into four conditions.  The systemic inflammatory response syndrome (SIRS) is 
defined as having two or more of the following symptoms: fever, rapid breathing 
(tachypnea), high heart rate (tachycardia), and high (leukocytosis) or low (leucopenia) 
white blood cell counts (Longo, 2012).  Sepsis is defined as SIRS with a suspected or 
proven infection, and severe sepsis includes patients that have sepsis with one or more 
signs of organ failure.  Septic shock, however, requires hypotension to be present (Angus 
and van der Poll, 2013; Longo, 2012). 
Sepsis and its associated conditions are a major cause of mortality and morbidity 
in the United States and worldwide, as they are responsible for greater than 750,000 cases 
each year in the United States and an estimated 19 million cases around the globe 
(Adhikari et al., 2010; Angus and van der Poll, 2013; Cohen, 2002; Hotchkiss and Karl, 
2003).  This adds up to 2% of all hospital admissions, which is a huge economic burden.  
In fact, hospital costs for patients with severe sepsis amounted to $24.3 billion in 2007 
and was averaged to around $20,000 per case (Lagu et al., 2012).  Within the ICUs, 
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sepsis is to blame for 10% of admissions (Angus et al., 2001; Angus and van der Poll, 
2013).  Even with antibiotics and modern medicine, mortality rates remain high, hovering 
between 30 and 50% (Angus et al., 2001; Angus and van der Poll, 2013; Cohen, 2002; 
Hotchkiss and Karl, 2003).   
 
Etiology 
 The primary site of infection varies among septic patients, but it is most 
frequently caused by respiratory infections, as 40-60% of all septic patients have 
causative respiratory infections (Alberti et al., 2002; Angus et al., 2001; Vincent et al., 
2009).  Thus, in addition to the important complications of pneumonia alone, its role in 
predisposing patients to sepsis makes it particularly deadly.  Intra-abdominal and urinary 
tract infections are other major sites of origin (Alberti et al., 2002; Angus et al., 2001; 
Angus and van der Poll, 2013; Vincent et al., 2009).  The bacterial species most 
commonly associated with sepsis are Gram-negative pathogens, such as E. coli, 
Pseudomonas species, and K. pneumoniae, which are detected in about 60% of all cases.  
Gram-positive bacteria were observed in around 40% of cases, with S. aureus, S. 
pneumoniae, and Staphlococcus epidermidis being the predominant species present (Opal 
et al., 2003; Vincent et al., 2009).   
There are several risk factors associated with sepsis, the primary one being age.  
The incidence of sepsis increases dramatically with age, with 5.3 per 1,000 cases in 
adults age 60-64 increasing to 26.2 per 1,000 cases in the elderly over 85 years of age 
(Angus et al., 2001).  The incidence of pneumonia alone in adults 85 years and over is 
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almost double, with 40 per 1,000 cases, demonstrating the link between the two 
conditions, as pneumonia is the number one cause of sepsis.  Interestingly, gender plays 
an important role in susceptibility as well, with men having increased incidence and 
mortality rates than women of the same age (Angus et al., 2001).  Underlying conditions 
and immunosuppression are also notable risk factors (Angus and van der Poll, 2013). 
 
Pathology and Immune Response 
The immune response during sepsis is comprised of both pro- and anti-
inflammatory mechanisms that can contribute to pathogen clearance, tissue recovery, and 
risk of secondary infections, but can also lead to severe immunopathology (Angus and 
van der Poll, 2013).  Bacteria and their immunogenic products (predominantly 
lipopolysaccharide [LPS] in Gram-negative infections) are recognized through PRRs on 
leukocytes and endothelial cells, and elicit a primary inflammatory response (Angus and 
van der Poll, 2013; Cohen, 2002).  This response is characterized by immune cell 
activation (specifically of circulating monocytes and neutrophils), release of 
proinflammatory cytokines, complement and coagulation cascade activation, and 
eventually cellular necrosis (Angus and van der Poll, 2013; Cohen, 2002).  Tissue 
damage is thought to be a result of proinflammatory processes aimed at clearing 
pathogens.  Coagulation defects, including disseminated intravascular coagulation (DIC), 
are prominent features of severe sepsis and play an important role in perpetuating the 
cycle of inflammation.  DIC, defined as aberrant intravascular fibrin deposition, is a 
condition caused predominantly by sepsis.  It is brought about by excessive tissue factor 
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activity (Longo, 2012), which de-represses protein C (a coagulation inhibitor) and 
stimulates the coagulation cascade, eventually ending in fibrin deposition (Angus and van 
der Poll, 2013; Levi and van der Poll, 2010).  These same proteases that mediate 
coagulation, also induce inflammation by activating protease-activated receptors (Angus 
and van der Poll, 2013; Cohen, 2002).   
While the inflammatory response of sepsis causes great collateral damage and 
tissue injury, the secondary anti-inflammatory response needed to control inflammation 
paradoxically leads to reduced immunoresponsiveness and is thought to be equivalently 
dangerous.  In fact, multiple studies have shown increased apoptosis of immune cells, 
expansion and increased activity of regulatory cells (such as myeloid-derived suppressor 
cells and T regulatory lymphocytes), and neuroendocrine regulation of the inflammatory 
response during the anti-inflammatory phase of sepsis.  Together, this decreased 
immnuoresponsiveness induces an immunosuppressed state (Angus and van der Poll, 
2013; Cohen, 2002; Hotchkiss et al., 2009; Hotchkiss et al., 2013; Reddy et al., 2001b).  
This immunosuppression leads to increased susceptibility to secondary infections, 
including hospital-acquired pneumonia, which, in turn, causes significant morbidity and 
mortality (Cohen, 2002; Dellinger et al., 2013; Hotchkiss et al., 2013). 
 
Sepsis-Induced Immunosuppression 
There have been multiple reports detailing the functional consequences of sepsis-
induced immunosuppression.  Post-mortem studies have revealed active opportunistic 
infections in patients who died from sepsis (Otto et al., 2011; Torgersen et al., 2009), and 
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peripheral blood mononuclear cells isolated from septic patients showed a dramatic 
decrease in proinflammatory cytokine production and responsiveness after ex vivo 
stimulation (Ertel et al., 1995; Munoz et al., 1991; van der Poll and Opal, 2008; van 
Dissel et al., 1998).  Additionally, various immune cells, including B cells, both cluster of 
differentiation-4 (CD4) and CD8 T cells, and dendritic cells, necessary to mount an 
effective response against opportunistic infections, are more apoptotic in patients with 
severe sepsis.  Moreover, prevention of immune cell apoptosis in mouse models has 
improved survival of sepsis, implicating cell death as a physiological mechanism 
associated with the pathogenesis of sepsis-induced immunosuppression (Hotchkiss et al., 
2013; Reddy et al., 2001b).  Other cellular and humoral antimicrobial functions, such as 
reactive oxygen species (ROS) generation, phagocytosis, and neutrophil chemotaxis and 
function are also impaired in septic patients (Angus and van der Poll, 2013; Cohen, 2002; 
Hotchkiss et al., 2013; Reddy et al., 2001a).  Dysfunction of the immune system causes 
increased susceptibility to secondary, hospital-acquired infections like pneumonia.   
 
Relationship to Pneumonia 
 Sepsis and pneumonia are both inflammatory diseases and are integrally linked.  
As stated above, pneumonia is the number one cause of sepsis, with 40% of septic 
patients having a primary respiratory infection (Angus et al., 2001; Vincent et al., 2009).  
Furthermore, patients with severe sepsis are more likely to develop pneumonia (Alberti et 
al., 2002), and ventilator-associated pneumonias develop in 10-30% of mechanically 
ventilated, septic shock patients (Chastre and Fagon, 2002).  Multiple studies have shown 
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the deleterious effect of sepsis on pneumonia outcomes.  Using different mouse models 
of sepsis, including cecal-ligation and puncture (CLP) and endotoxemia, different groups 
have shown increased mortality to various pulmonary bacterial challenges (Benjamim et 
al., 2010; Delano et al., 2010; Jung et al., 2012).  Additionally, pulmonary host defense is 
compromised in these same models and was associated with decreased pulmonary 
cytokine responses and airway neutrophil recruitment (Benjamim et al., 2010; Cao et al., 
2014; Carrick et al., 1997; Frevert et al., 1994; Nelson et al., 1990; Reddy et al., 2001a; 
Wagner et al., 1999; Wagner et al., 2002; White et al., 1986).  Work by other groups 
using these same mouse models suggested that both interleukin-10 (IL-10) and IL-1 
receptor associated kinase M mediate sepsis-induced immunosuppression of lung 
immunity (Deng et al., 2006; Reddy et al., 2001a; Steinhauser et al., 1999).   
 
Treatments and Therapeutics 
The current treatment recommendation for sepsis, septic shock, and severe sepsis 
is antibiotic therapy to control the infection as well as any supportive care necessary to 
stabilize the patient (Angus and van der Poll, 2013; Longo, 2012).  Presently, there are no 
Food and Drug Administration approved therapeutics available for the treatment of 
sepsis.  In the past 30 years, there have been multiple clinical trials focusing on severe 
sepsis treatments, but none have proven fruitful (Angus and van der Poll, 2013).  These 
therapeutics were aimed at countering different arms of septic pathologies.  For example, 
multiple trials were designed to counter the initial inflammatory cascade with either anti-
LPS or anti-proinflammatory agents, while others more recently were intended to 
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modulate the coagulation cascade (Abraham et al., 1995; Angus and van der Poll, 2013).  
The most recent trial, involving an activated, recombinant protein C (Drotrecogin Alfa 
[Activated]), was approved after the initial trial showed an improvement in mortality 
among patients with severe sepsis (Dhainaut et al., 2003; Opal et al., 2003).  It wasn’t 
until a recent, second clinical trial in which the efficacy of Drotrecogin Alfa (Activated) 
was disproven, and the drug was taken off of the market (Angus and van der Poll, 2013; 
Ranieri et al., 2012).  Both intravenous Ig and statins have been associated with improved 
outcomes of severe sepsis, but neither is currently in clinical trials or part of the standard 
of care (Dellinger et al., 2013; Laupland et al., 2007; Yende et al., 2011).  It is 
unsurprising, however that one specific treatment or therapeutic has not been successful 
in improving sepsis outcomes for all patient groups, as sepsis is a very heterogeneous 
syndrome affecting numerous populations with a multitude of bacterial etiologies.  
Perhaps the most effective treatments will be tailored to specific population groups and 
utilize a number of combined therapies.    
 
Innate Immunity During Pneumonia 
Alveolar Macrophage Activation and Functions 
 Alveolar macrophages are considered the sentinel cells in airspaces and are the 
first line of leukocytic defense against respiratory infections.  They are long-lived, 
phagocytic cells within the lungs that alert other leukocytes to the presence of microbes.  
Pathogens are recognized through various PRRs on the cell surface that recognize 
conserved motifs common to pathogens, the most well know being the Toll-like receptors 
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(TLRs) (Hussell and Bell, 2014; Mizgerd, 2008; Werner and Steele, 2014).  There are 
currently 13 discovered TLRs, nine of which are active in both mice and humans, and 
each recognizing different pathogen associated molecular patterns such as LPS, flagellin 
and viral ribonucleic acids (RNAs) (Kawai and Akira, 2010; Takeda and Akira, 2005).  
Recognition of lower respiratory pathogens by PRRs has been comprehensively reviewed 
elsewhere (Eddens and Kolls, 2012; Mizgerd, 2008).  TLRs are particularly relevant 
sensors for detecting bacteria in the lungs, as exemplified by ablated defenses in whole 
body knockout mouse model of MyD88, which is an adaptor protein that is shared 
amongst this family of receptors (Skerrett et al., 2004).  TLR4 recognition of Gram-
negative respiratory infections such as E. coli occurs primarily through recognition of 
LPS (Branger et al., 2004), while TLR2 senses Gram-positive S. pneumoniae infections 
through peptidoglycan, a bacterial cell wall component (Dessing et al., 2007; Knapp et 
al., 2004; Koedel et al., 2003; Lee et al., 2007; Mogensen, 2006).  TLR2 can also activate 
macrophages through recognition of the acute phase protein (APP), serum amyloid A 
(SAA) (Cheng et al., 2008).  Interestingly, pneumolysin, an important pneumococcal 
virulence factor, causes TLR4 activation, implying a synergistic effect of multiple PRRs 
(Lee et al., 2007; Malley et al., 2003).  In addition to TLRs, macrophage receptor with 
collagenase structure is also important in initiating responses to pneumococcal infections, 
as knockout mice have decreased bacterial clearance and killing (Arredouani et al., 2004; 
van der Poll and Opal, 2009).   
 Microbe recognition by TLRs initiates a signaling cascade culminating in nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and interferon regulatory 
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factor activation, leading to the production of a myriad of proinflammatory factors 
including cytokines and chemokines.  The importance of alveolar macrophage NF-κB 
signaling in initiating the immune response can be seen in a myeloid-specific NF-κB 
knockout.  After a pneumococcal infection, cytokine responses and neutrophil 
recruitment are delayed (Pittet et al., 2011).  Early response cytokines tumor necrosis 
factor-α (TNFα), IL-1, and interferon-γ, which are induced by NF-κB activation, act in 
an autocrine and paracrine fashion to initiate the inflammatory cascade in nearby 
macrophages and epithelial cells.  This feed-forward loop results in the secretion of 
additional proinflammatory cytokines and chemokines such as CXCL1, CXCL2, and 
CCL2, prompting the recruitment of neutrophils and monocytes into the airspaces 
(Aggarwal et al., 2014; Herold et al., 2011; Mizgerd, 2008).   
Along with recruited neutrophils, macrophages potentiate pathogen clearance.  
Alveolar macrophages not only coordinate immune responses from other cells, but they 
also directly eliminate bacteria through phagocytosis and release of noxious free radicals 
and proteases, such as reactive oxygen species (ROS), reactive nitrogen species, matrix 
metalloproteinases (MMPs), and lysozyme (Aggarwal et al., 2014; Mizgerd, 2008; Sibille 
and Reynolds, 1990).  Secretion of these toxic substances, however, induces tissue injury 
and plays an important role in the development of ALI and ARDS (Aggarwal et al., 2014; 
Sibille and Reynolds, 1990; van der Poll and Opal, 2009).  Following bacterial clearance, 
alveolar macrophages also function to promote tissue resolution and the clearance of 
apoptotic neutrophils (Bratton and Henson, 2011; Henson and Bratton, 2013; Herold et 




Neutrophils and Their Function in Pneumonia 
 Neutrophil recruitment is a hallmark of pneumonia and occurs early during 
infection.  Both alveolar macrophages and epithelial cells play an important role in their 
recruitment, and pathogen clearance is not as efficient without them, as antibody 
depletion of neutrophils results in increased bacterial outgrowth and mortality following 
infection (Garvy and Harmsen, 1996; Kadioglu et al., 2000; van der Poll and Opal, 2009).  
Once alveolar macrophages sense pathogens in the airspaces, alveolar epithelial cells are 
stimulated by early response cytokines to induce additional inflammatory cytokines and 
chemokines, and these factors cooperate to drive neutrophil emigration into the airspaces 
(Aggarwal et al., 2014; Quinton and Mizgerd, 2015; van der Poll and Opal, 2009).   
 Once recruited, neutrophils are responsible for the majority of pathogen clearance 
from the alveolar space.  Similar to macrophages, neutrophils can phagocytose bacteria 
and release antimicrobial molecules including ROS and proteases.  Neutrophils are 
granulocytic cells that have four types of granules: azurophilic or primary granules, 
specific or secondary granules, gelatinase or tertiary granules, and secretory vesicles.  
Primary and secondary granules are released once neutrophils have entered the lungs and 
contain neutrophil elastase, myeloperoxidase (MPO), defensins, lactoferrin, lysozyme, 
MMPs and other bactericidal proteins (Borregaard and Cowland, 1997; Grommes and 
Soehnlein, 2011).  While release of antimicrobial molecules is one of the main 
mechanisms of pathogen clearance, their toxic nature causes collateral tissue damage and 
	  	  
18	  
is a major cause of ALI (Grommes and Soehnlein, 2011; Mantovani et al., 2011; 
Tamakuma et al., 2004). 
 In addition, neutrophils have adapted a unique form of bacterial killing using 
neutrophil extracellular traps (NETs).  Upon activation, granulocytes release genetic 
material laced with antimicrobial components, which trap and kill invading microbes 
(Brinkmann and Zychlinsky, 2007; Brinkmann and Zychlinsky, 2012).  ROS activity 
seems to be necessary for this process and microscopy has confirmed that the release of 
NETs occurs through cell membrane rupture and eventual cell death, a process coined 
“NETosis”.  Moreover, NETs have been shown to bind to both Gram-negative and Gram-
positive bacteria (Brinkmann and Zychlinsky, 2007; Brinkmann and Zychlinsky, 2012). 
 
Cytokines/Chemokines 
 Cytokines and chemokines are the molecular messengers within the airspaces.  As 
mentioned earlier, TNFα and IL-1 are early response cytokines, which act as alarm 
signals and induce the inflammatory cascade, and their importance during lung infections 
was shown before using various mouse models, as detailed above (Jones et al., 2005; 
Mizgerd et al., 2004; Mizgerd et al., 2001; van der Poll et al., 1997a).  Additionally, 
evidence from a clinical trial for rheumatoid arthritis has shown the necessity for TNF 
and IL-1 to protect against pneumonia in humans, as combining the TNF receptor fusion 
protein (etanercept) with an IL-1 receptor antagonist (anakinra) significantly increased 
the risk of lung infection (Genovese et al., 2004).  IL-6 is another major cytokine 
necessary for host defense during lung infections, as knockout mice show defects in host 
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defense (Jones et al., 2006; van der Poll et al., 1997b).  Patients with a unilateral 
pneumonia are reported to have an increase in IL-6 in the involved lobe compared to 
uninvolved lobes (Dehoux et al., 1994), and IL-6 is increased in human subjects after 
instillation of endotoxin into the lungs (O'Grady et al., 2001).  Moreover increases in IL-6 
were associated with lymphocytosis in the bronchoalveolar lavage fluid (BALF) of 
patients with idiopathic interstitial pneumonia, suggesting that IL-6 regulates pulmonary 
inflammation during pneumonia in humans as well as mice (Park et al., 2000).  Recently, 
IL-17 has gained more notoriety with its involvement in lung infections.  Patients with 
Hyper IgE Syndrome have mutations in the transcription factor signal transducer and 
activator of transcription-3 (STAT3), which leads to an increased occurrence of lung 
infections in this patient population.  These patients have defective T helper 17 cells and 
decreases in its main effector cytokine, IL-17, suggesting that this cytokine plays an 
important role in pulmonary resistance to infection (Eddens and Kolls, 2012; Mizgerd, 
2003; Quinton and Mizgerd, 2015).  Other cytokines dependent on STAT3 activity, 
leukemia inhibitory factor (LIF) and oncostatin-M (OSM), work upstream to activate 
STAT3, and are necessary for tissue protection and neutrophil recruitment, respectively, 
during E. coli pneumonia (Quinton et al., 2012b; Traber et al., 2015).  Both have been 
implicated in human pneumonia, as LIF is increased in the BALF of patients with ARDS 
(Jorens et al., 1996), and OSM is produced by human neutrophils and is increased in the 
BALF of pneumonic patients (Grenier et al., 2001; Grenier et al., 1999).  Multiple other 
cytokines, including the anti-inflammatory cytokine IL-10 and IL-1 receptor antagonist, 
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and their roles in acute respiratory infections have been reviewed by others (Eddens and 
Kolls, 2012; Mizgerd, 2008; Quinton and Mizgerd, 2015).  
 Chemokines are small molecules, similar to cytokines, that are necessary to 
recruit leukocytes to the site of infection (Standiford et al., 1996).  Chemokines are 
classified based on the spacing of the cysteine residues in the N terminal region, and are 
denoted as being part of the C, CC, CXC, CX3C chemokine family, where the X denotes 
amino acids between the two cysteine residues.  Both CXCL1 and CXCL2 are two 
important chemokines in pneumonia, as they are produced by a number of cell types and 
are the main chemokines responsible for neutrophil recruitment into the airways (Le et 
al., 2004; Mizgerd, 2008; Quinton and Mizgerd, 2015; Standiford et al., 1996).  CXCL5, 
CCL20 and GM-CSF are alveolar epithelial cell-specific and also play an important role 
in granulocyte recruitment during bacterial pneumonia (Quinton and Mizgerd, 2015; 
Yamamoto et al., 2014; Yamamoto et al., 2012).  In addition to the chemokines 
mentioned above, GM-CSF and granulocyte colony-stimulating factor (G-CSF) are 
growth factors necessary for maximal neutrophil recruitment.  Both GM- and G-CSF 
control the mobilization and maturation of neutrophils from bone marrow and GM-CSF 
also has a significant effect on monocyte/macrophage recruitment (Quinton and Mizgerd, 
2011; Quinton and Mizgerd, 2015; Shi et al., 2006).  In fact, G-CSF restores circulating 
neutrophil counts in patients with neutropenia (Welte et al., 1996) and is increased after 
endotoxin delivery to the airways in humans (O'Grady et al., 2001).  Standiford, et al. has 




Acute Phase Response 
History and Definition 
 The acute phase response (APR) is a conserved hepatic response that is defined as 
significant (at least 25%) increases or decreases in circulating APP concentrations.  The 
APR was first observed in 1930 with the discovery of a pneumococcus-reactive 
serological fraction (fraction “C”, later named C-reactive protein [CRP]) in samples from 
pneumonic patients (Tillett and Francis, 1930).  This protein and others would later be 
coined as acute phase-reactants (Abernethy and Avery, 1941; MaCleod and Avery, 1941; 
McCarty, 1947).  The APR is commonly used as a biomarker, but its functional and 
physiological role has yet to be elucidated.  CRP continues to be utilized as a biomarker 
for infection and cardiovascular disease (Cals et al., 2009; Du Clos, 2000; Ridker, 2008), 
and other APPs, including SAA, serum amyloid P (SAP), LPS-binding protein (LBP) and 
ferritin have been used as biomarkers for diseases including cancer, sepsis and 
Alzheimer’s (Armstrong, 2006; Beard et al., 2006; de Torre et al., 2006; Le, 2005; Sakr 
et al., 2008; Urieli-Shoval et al., 2000; Verwey et al., 2008).  The functional properties of 
multiple APPs have been identified, including several of which are particularly relevant 
to immunity and inflammation (see below).  But the physiological significance of the 




Functions of Select, Relevant Acute Phase Proteins 
Historically, there have been over 40 liver-derived APPs identified, each with its 
own individual function (Gabay and Kushner, 1999; Moshage, 1997; Suffredini et al., 
1999).  APPs can be categorized based on their function, many of them playing a role in 
the innate immune response (Table 1).  The complement system, one major, well-
appreciated group of APPs, is crucial in pathogen detection and in induction of the 
inflammatory cascade (Bode et al., 2012; Doan, 2013; Gabay and Kushner, 1999; 
Suffredini et al., 1999).  This group consists of opsonins (C3), pathway activators and 
regulators (mannose-binding lectin, C4, factor B, C4b-binding protein, and C1 inhibitor), 
and parts of the membrane-attack complex (C9), which is necessary for bacterial lysis 
(Bode et al., 2012; Suffredini et al., 1999).  Another group important for pathogen 
recognition and inflammation are the secreted pathogen recognition receptors and 
opsonins.  Short pentraxins, like CRP and SAP, as well as LBP are among the most 
widely recognized (Bode et al., 2012; Du Clos, 2000; Suffredini et al., 1999; Wurfel, 
1995).  LBP plays a major role in TLR4 activation by bringing LPS together with CD14 
and TLR4 to help initiate inflammation (Akira and Takeda, 2004; Chow et al., 1999).  
Other APPs, namely SAA, have been implicated in leukocyte activation, including that 
mediated by TLR2 and induce phagocytosis (Anthony et al., 2013; Bode et al., 2012; 
Cheng et al., 2008; Shah et al., 2006; Suffredini et al., 1999; Uhlar and Whitehead, 1999).  
Another group of APPs are those necessary for inducing and regulating the coagulation 
cascade.  Prothrombin, fibrinogen, factor VIII, antithrombin, plasminogen, and others are 
important activators of the clotting response, while proteinase inhibitors such as α1-
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antichymotrypsin, antitrypsin, and α2-macroglobulin can have regulatory effects.  Metal 
chelating and transport proteins, like haptoglobin, hemopexin, and ferritin are also 
considered APPs whose function is to sequester important metals necessary for bacterial 
growth (Bode et al., 2012; Gabay and Kushner, 1999; Moshage, 1997; Suffredini et al., 
1999). 
 
Table 1. Functions of select, relevant APPs 
APP Function 
Complement (C3, Manose 
Binding Lectin, C4, Factor B, 
C1 Inhibitor, C9) 
Opsonization of Pathogens, pathway regulators, 
bacterial lysis 
C-reactive protein Opsonin, complement activation, mediates phagocytosis 
Serum Amyloid A Leukocyte activation (some through TLR2) 
Serum Amyloid P Opsonin, leukocyte activation 
LPS-Binding Protein Recognizes and binds LPS, brings LPS together with CD14 to induce TLR4 activation 
Fibrinogen, prothrombin, 
antithrombin, etc. Key regulators of the coagulation cascade 
Lipocalin2, hemopexin, 
haptoglobin 
Metal chelators, sequester minerals necessary for 
bacterial growth 
 
Regulation of the Acute Phase Response 
 The hepatic APR is mainly regulated by two major pathways: those downstream 
of IL-6 and those initiated by the early response cytokines IL-1 and TNFα.  Indeed, 
knockout mouse models show this to be true, as IL-6 deficient mice challenged with 
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turpentine or Listeria monocytogenes had ablated APP production (Kopf et al., 1994), 
and a similar APP defect was seen following turpentine or LPS treatment in either IL-1 
receptor 1 (IL-1R1) deficient, TNF receptor 1 (TNFR1) and TNFR2 double knockout, or 
IL-1β deficient mouse models (Leon et al., 1996; Leon et al., 1997; Zheng et al., 1995).  
IL-6 and early response cytokines predominantly signal through STAT3 and NF-κB 
RelA (also know as p65), respectively, and the necessity of these two transcription 
factors in the regulation of APP expression has been shown through multiple promoter 
analysis and biochemical studies.  For instance, deletions of STAT3 or NF-κB promoter 
sites in SAP and SAA, respectively, rendered these promoters inactive (Betts et al., 1993; 
Hagihara et al., 2005; Ochrietor et al., 2000), and hepatocytes lacking NF-κB activity 
show reduced CRP expression (Patel et al., 2007).  Additionally, endotoxin-induced APP 
expression is significantly reduced in conditional STAT3 knockouts (Alonzi et al., 2001), 
and treatment with TNFα, IL-1 and IL-6 can induce APP expression in mice (Agrawal et 
al., 2003; Betts et al., 1993; Gabay and Kushner, 1999).   
The studies detailed above implicate IL-6 and early response cytokine signaling 
(through STAT3 and NF-κB, respectively) as the major regulators of the hepatic APR, 
and thus led to the creation of a double knockout mouse model of APR deficiency.  To 
establish this, STAT3 and RelA were specifically and effectively targeted for deletion in 
hepatocytes using the Cre-LoxP system.  Mice bearing homozygous floxed alleles for 
Stat3 and RelA (Algul et al., 2007; Takeda et al., 1998) were crossed onto a background 
containing a transgenic Cre-recombinase under the transcriptional control of an albumin 
promoter (Alb-Cretg/-/ Stat3LoxP/LoxP/ RelALoxP/LoxP) (Quinton et al., 2012a).  Consequently, 
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hepatic APP changes were virtually abolished in response to all stimuli tested, including 
intrapulmonary bacterial infections, intravenous cytokines, and subcutaneous casein (a 
sterile irritant known to induce the APR), indicating that hepatocyte STAT3 and RelA 
function cooperatively to induce the liver APR (Quinton et al., 2012a).   
 
Kinetics of the Acute Phase Response 
 The induction of the APR happens relatively quickly in response to an 
inflammatory stimulus, and can vary depending on the type of stimulus itself.  During an 
E. coli lung infection, liver STAT3 and NF-κB activation peak by six hours of infection, 
with activation observed after only two hours of infection.  This liver activation was 
associated with induction of hepatic APP transcripts after only six hours of infection 
(Quinton et al., 2009).  APP induction is occurs more slowly in response to a 
pneumococcal lung infection, as liver STAT3 and RelA activation peaked around 15 
hours of infection.  Additionally, liver APP transcript induction after S. pneumoniae 
infection was similarly observed as early as 15 hours post infection (Quinton et al., 
2009).  APR stimulation also occurs within six hours after endotoxemia, as STAT3 
activation is observed 4.5 hours post-i.p. LPS injection with APP induction by six hours 
(Alonzi et al., 2001).  These studies suggest, just as its name does, that the APR occurs 
quickly and acutely after inflammation.  Importantly, the liver responses we have 
observed are consistent with an earlier release of the required upstream cytokines, TNF, 
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IL-1, and IL-6, supporting the critical role for these cytokines in eliciting a downstream 
hepatic APR (Quinton et al., 2009).      
      
Acute Phase Response During Pneumonia: The Lung-Liver Axis 
In addition to initiating an APR, IL-6, TNFα, and IL-1 are critical determinants of 
lung defense.  Using triple mutant mice, lacking all signaling receptors for TNFα and IL-
1 (TNFR1-/-/TNFR2-/-/IL-1R1-/-), Jones et al. showed the necessity of these early response 
cytokines during pneumonia to induce the inflammatory cascade and drive neutrophil 
recruitment to the lungs, and other groups have used the same mouse model and a 
neutralizing TNFα antibody during pneumonia to show similar results (Jones et al., 2005; 
Mizgerd et al., 2004; Mizgerd et al., 2001; van der Poll et al., 1997a).  Moreover, IL-6 
deficient mice show defects in bacterial clearance and lung defense after pulmonary 
infection with either E. coli or S. pneumoniae (Jones et al., 2006; van der Poll et al., 
1997b).  The importance of these pulmonary host defense cytokines in the induction of 
the hepatic APR was elucidated using these same mouse models.  Intrapulmonary LPS 
treatment induced systemic and BAL APP protein and hepatic APP mRNA expression in 
wildtype mice.  This response was IL-6-dependent, as systemic IL-6 neutralization or IL-
6-/- mice had diminished hepatic APP expression and plasma APP concentrations 
(Gamble et al., 2009; Vernooy et al., 2005).  Furthermore, APR inhibition during both 
Gram-negative, E. coli and Gram-positive, S. pneumoniae pneumonias in IL-6-/- mice was 
associated with decreased liver STAT3 activation (Quinton et al., 2009), and similarly, 
triple mutant mice also exhibited defective APP induction after S. pneumoniae and E. coli 
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pneumonias that was associated with decreased hepatic NF-κB RelA nuclear 
translocation (Quinton et al., 2009).  In humans with Hyper IgE syndrome, 
polymorphisms in STAT3 render it transcriptionally inactive (Holland et al., 2007; 
Minegishi et al., 2007).  Because of this, these patients suffer from repeated bacterial 
pneumonias, mostly due to S pneumoniae, H. influenzae, and S. aureus, suggesting that 
STAT3 in humans is necessary to mount effective pulmonary defense (Freeman et al., 
2007).  The ability of these specific host defense cytokines to facilitate both lung defense 
and hepatic APP expression suggests a role for liver activation in the local immune 
response.  
 Presently, there are remarkably few studies that were designed to evaluate the net, 
functional role of the APR during inflammation of any kind, including that triggered by 
lung infections.  A handful of groups have shown functional consequences of the APR 
during inflammation.  Hepatic STAT3-dependent APPs were protective in response to 
both systemic LPS and a CLP model of sepsis, as hepatocyte STAT3-/- mice had 
increased inflammatory cytokine production (Sakamori et al., 2007).  Other studies 
interrogated the role of a turpentine-induced, preexistent APR on pulmonary 
inflammation and host defense.  After pulmonary challenges with P. aeruginosa or A. 
baumannii, Renckens et al. observed impaired host defense and pulmonary cytokine 
responses in pretreated mice, suggesting that a preexistent APR dampens local immune 
responses (Renckens et al., 2006; Renckens et al., 2008).  While informative, these 
specific studies induce an APR through turpentine injection, the offhand affects of which 
are unknown.  By utilizing the above-mentioned APR-null mouse model, Quinton et al. 
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determined the necessity of the APR during pneumococcal pneumonia for survival and 
systemic host defense.  APR-null mice had significantly decreased opsonophagocytosis 
and bacterial complement deposition in the circulation, leading to increased bacteremia in 
hepSTAT3/RelA-/- mice lacking STAT3 and RelA in hepatocytes (Quinton et al., 2012a).  
The data suggest that not only does the APR function to limit bacterial dissemination 
during pneumonia, but also that key lung defense cytokines (IL-6 and the early response 
cytokines) activate hepatic STAT3 and RelA to induce the APR, forming a “lung-liver 
axis” (Figure 1).  However, those studies were not specifically empowered to observe 
effects of the APR on lung inflammation itself due to the highly virulent strain of 
pneumococcus used. 
Other studies have interrogated the role of specific APPs in pneumonia.  
Infections in LBP deficient mice show its necessity to facilitate bacterial clearance and 
inflammation after intrapulmonary K. pneumoniae and LPS, respectively (Branger, 2004; 
Brass et al., 2004; Fan et al., 2002; Knapp et al., 2006), while other groups have shown 
that LBP over-expression reduces mortality and improves respiratory function during 
Gram-negative pneumonia (Hemmila et al., 2006).  Additionally, mice deficient in SAP 
could not mount an early inflammatory response during Gram-positive S. pneumoniae 
pulmonary infection (Yuste et al., 2007) and, in a mouse model of pulmonary fibrosis, 
SAP-/- mice had increased pulmonary fibrosis and inflammation (Pilling and Gomer, 
2014).  Complement has also been determined as a necessary component of pulmonary 
host defense and inflammation (Czermak et al., 1998; Younger et al., 2003).   While these 
studies are notable, the knockout mouse models used are whole body and not liver-
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specific, making it hard to delineate the specific role of liver-derived APPs during lung 
infections.  Additionally, individual APP deletions would affect baseline levels and 
changes due to the APR itself, and deletion of just one APP does not ablate the entire 
APR, again making it difficult to elucidate the function of the hepatic APR as a whole.  
Even with these limitations, these studies suggest that the APR and its individual APPs 
play a more biologically important role in lung infections than previously appreciated, 
indicating a need for a deeper understanding of the role of the APR as a whole (in 




Figure 1. The Lung-Liver Axis.   
Upon entrance into the lower respiratory tract, pathogens initiate an immune response 
that includes cytokine production and leukocyte recruitment.  Cytokines critical to 
pulmonary defense, IL-6, TNFα, and IL-1, then activate key hepatic transcription factors, 
STAT3 and NK-κB RelA, respectively, to induce the expression and production of APPs, 
thus initiating the APR.  The various APPs then circulate throughout the body, possibly 
to the original site of infection, where they can gain access to injured airspaces.  The 
function of the APR as a whole during lung infections is poorly understood.   
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Specific Aims and Hypothesis 
 As described earlier, the hepatic APR is a virtually ubiquitous response to 
inflammation or injury, including that caused by pneumonia and/or sepsis.  Specific 
functions of individual APPs have been recognized, but other than its common use as a 
biomarker, the biological role of the APR has yet to be elucidated, especially in 
pneumonia.  Induction of the APR requires critical pulmonary host defense cytokines to 
activate key hepatocyte transcription factors, STAT3 and NF-κB RelA, suggesting that 
pneumonia induces a systemic response in the liver by effectively creating a lung-liver 
axis.  Our laboratory has recently created an APR-null mouse model in which hepatocyte 
STAT3 and RelA were functionally deleted.  This mouse model revealed a systemic 
necessity for the APR in protecting against bacterial dissemination during pneumococcal 
pneumonia, but these studies were not empowered to determine the role of the APR on 
local inflammation and host defense in the lungs themselves.  Additionally, other groups 
have shown the requirement of hepatic STAT3 activation for survival during sepsis, but 
none have interrogated whether or how this response influences pneumonia biology.  
Uncovering a functional role of the hepatic APR will provide valuable avenues of 
research for potential therapeutics, prognostics, or diagnostics during both pneumonia 
and sepsis, conditions where present treatments are sorely lacking.  Furthermore, the liver 
is a more targetable organ than the lungs and has great potential for small molecule 
modulation of the APR to help patients with or at risk for pneumonia.  Thus, the goal of 
this research was to understand the functional role of the liver APR in lung biology 
during pneumonia, along with whether or how such a response can be modified in the 
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context of sepsis.  We propose that circulating plasma proteins, including APPs, 
extravasate into the injured airspaces during infection and regulate the pulmonary 
immune response.  It is feasible that circulating APPs gain access to the infected 
airspaces as serum components flood injured lungs.  Our rationale is based largely on 
studies in which the APR is chemically induced prior to pneumonia and is shown to 
regulate the inflammatory response.  Taken together, these findings led us to hypothesize 
that the APR plays a functional, protective role in the pulmonary immune response 
during pneumonia.  This dissertation is divided into two main research aims.  In the 
first, we determine if the APR maintains pulmonary defense and inflammation during E. 
coli pneumonia, and whether this is modulated in a cell-specific manner.  In the second, 
we aim to interrogate the direct influence of a pre-existing, endotoxemia-induced APR on 





CHAPTER TWO: MATERIALS AND METHODS 
 
Mouse Models 
Mouse experiments were performed using hepatocyte-specific functional 
deletions of either STAT3 alone or STAT3 in combination with RelA using the Cre-LoxP 
system driven by an albumin promoter.  This is a well-established system that is specific 
to hepatocytes and enables Cre-recombinase gene expression (and gene targeting) by 6 
weeks of age (Postic and Magnuson, 2000).  We have previously verified the deletion of 
STAT3 and RelA liver protein using this system (Quinton et al., 2012a).  Mixed sexes 
were used between 6 and 12 weeks of age and each experiment was performed at least 
twice.  All animal protocols were approved by the Boston University Institutional Animal 
Care and Use Committee.  
Hepatocyte STAT3-/- Mice 
 Dr. S. Akira generated and provided our laboratory with floxed STAT3 mice 
(Stat3LoxP/LoxP).  Exon 21 of Stat3, which contains the tyrosine residue necessary for 
dimerization and therefore its function, is flanked by LoxP insertions (Takeda et al., 
1998).  Mice with homozygous floxed alleles for Stat3 were crossed with mice containing 
a Cre-recombinase transgene under the transcriptional control of an albumin promoter 
(purchased from Jackson Labs) to create a functional deletion of STAT3 specifically in 
hepatocytes (Alb-Cretg/-/Stat3LoxP/LoxP).  Results from hepSTAT3-/- mice were compared to 




Hepatocyte STAT3/RelA-/- Mice 
 Dr. R. Schmid generated and provided our laboratory with floxed RelA mice 
(RelALoxP/LoxP), in which exons 7-10 of NF-κB RelA are flanked by LoxP insertions.  
These exons encode the nuclear localization sequence and part of the Rel homology 
domain required for activation (Carpenter et al., 2012).  The floxed RelA mice were 
crossed with both Stat3 floxed mice and with mice containing the transgenic albumin-
driven Cre-recombinase to create two stable colonies: Alb-Cretg/-/ Stat3LoxP/LoxP/ 
RelALoxP/LoxP and Alb-Cre-/-/ Stat3LoxP/LoxP/ RelALoxP/LoxP.  The latter genotype was used as 
control mice, as they do not express Cre-recombinase, and were compared against 
littermates of the former genotype lacking both STAT3 and RelA in hepatocytes. 
 
Bacterial Stocks 
Two bacterial strains were used for all of the infections: E. coli serotype 
06:K2:H1 (American Type Culture Collection, #19138), which was utilized for the 
majority of the studies, and E. coli Xen14 (Caliper [now Perkin Elmer], #119223), which 
is a luminescent strain derived from the parental E. coli WS2572 strain that contains a 
stable copy of the entire lux operon from Photorhabdus luminescens in the bacterial 
chromosome.  Infections were all done with the non-luminescent E. coli unless otherwise 
stated.   
Bacterial stocks were made by growing bacteria overnight on sheep blood agar 
plates (BD Biosciences) or lysogeny broth (LB-also known as Luria broth) agar plates 
with 30 µg/ml of kanamycin (for Xen14 only) to select for the luminescent colonies.  
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Sixteen hours later, colonies were picked from the plates using sterile pipette tips and 
grown to log phase in sterile LB (with kanamycin for the Xen14 strain) at 37°C, shaking 
at 300 revolutions per minute (rpm).  Once broth was cloudy and grown to mid-log phase 
(for about 4 hours), 700 µl aliquots were mixed with 300 µl of a 50% sterile glycerol 
solution to make a 1 ml bacterial stock in a final concentration of 16% glycerol.  The 




 Mice were anesthetized by intraperitoneal (i.p.) injection of a mixture of ketamine 
(50 mg/kg) and xylazine (5 mg/kg).  Once unconscious, a single incision was made above 
the trachea and the tissue was cleared away to expose it.  A 24-gauge catheter was then 
inserted into the trachea, and a 50 µl bolus of saline containing E. coli was instilled into 
the left lobe to create a lobar infection.  Two different inoculums of E. coli were used in 
these studies: a milder inoculum of 4x105 CFU or a more severe inoculum of 1x106 CFU.  
Inoculums were confirmed by culturing serial dilutions of the instillate on blood agar 





Endotoxemia/Pneumonia Two-Hit Model 
 HepSTAT3-/- and hepSTAT3+/+ (control) mice were i.p. injected with 5 mg/kg of 
ultrapure LPS 18 hours before intratracheal (i.t.) instillation of 106 CFU of E. coli.  Mice 
were then euthanized 0-24 hours after i.t. infection by isoflurane overdose (Figure 2).  
 
 Intravenous anti-TNF Treatment 
HepSTAT3/RelA-/- or control hepSTAT3/RelA+/+ mice were treated with a 100 
µl, 5 mg/ml bolus of either a control IgG (Bio X-cell, clone HRPN) or an anti-TNFα 
antibody (Bio X-cell; clone XT3-11) by tail vein injection immediately prior to i.t. E. 




Figure 2. Two-Hit Endotoxemia/Pneumonia Model   
Mice were pretreated with 5 mg/kg of LPS intraperitoneally 18 hours before intratracheal 
infection with 106 CFU of E. coli.  Mice were then sacrificed 0, 6, or 24 hours after E. 
coli infection for various endpoint analyses. 
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Endpoint Tissue Collection 
Brochoalveolar Lavage 
Mice were euthanized at the indicated time points and the lungs were removed.  
The trachea, with the lungs and heart still attached, was slid over a 20-gauge blunted, 
stainless steel catheter, which was connected to a stop-cock with two different syringes 
attached—one filled with phosphate buffered saline (PBS) or lavage buffer (indicated in 
each specific method) used to wash the airspaces and another empty one used to collected 
the lavage fluid (Figure 3).   
Once secured to the catheter with surgical suture (Roboz Surgical), the lungs were 
lavaged 10 times with 1 ml of PBS or lavage buffer used per wash, with the first lavage 
collected in a separate 1-ml syringe.  All washes were then centrifuged at 300 x g for 5 
minutes at 4°C to pellet the cells.  The supernatant from the first lavage was aliquoted 
and stored at -80°C for protein analysis.  Pooled cells from all washes were counted using 
a hemacytometer and differential counts were determined after cytocentrifugation and 




Figure 3. Schematic of BAL setup  
The lungs were tethered to a stainless steel catheter that was attached to a stopcock 
connected to two different syringes. The syringe immediately above the lungs was filled 
with PBS or lavage buffer, which was pushed into the airspaces on milliliter at a time.  
The stopcock was then turned to allow the BALF to be pulled back from the lungs into 





Figure 4. BALF Processing Flow Chart   
The first wash of the lungs was collected separately from the other 9 washes.  Both sets 
of washes were then centrifuged at 300 x g for 5 min at 4°C.  The cell-free supernatant 
from the first wash was aliquoted and then stored at -80°C for future analysis, while the 
supernatant from the remaining washes were discarded.  The cells from all washes were 
pooled, counted, and centrifuged onto a slide using a Cytospin.  Following staining, 




 After euthanasia, blood was collected from the anterior vena cava with a 25-guage 
needle.  After collection, the blood was incubated in MiniCollect Z Serum Separator 
tubes (Greiner Bio-One) for 30 minutes at room temperature and then centrifuged for 15 
min at 1500 x g and 4°C for serum separation.  The serum was collected, aliquoted, and 
stored at -80°C for future protein analysis.  For CFU analysis, the needle was heparinized 
and no serum separation occurred. 
Lung and Blood CFU Analysis 
At the indicated time points, mice were sacrificed and lung lobes were removed 
without the connective tissue and put into Bullet Blender 5 ml tubes containing 7-9 3.2-
mm diameter stainless steel Bullet Blender beads (Next Advance) and 400 µl of 1x 
protease inhibitor (Roche) in sterile water.  Once homogenized using the Bullet Blender 
(Next Advance), lung homogenates were brought up to 5 ml with the 1x protease 
inhibitor solution.  Homogenates and heparinized blood were then serially diluted in 
sterile water and plated on sheep blood agar plates.  After an overnight incubation at 






Lung RNA Isolation 
After lavage, the left lobe was isolated and homogenized in buffer RLT (from 
Qiagen RNeasy kit) and RNA was isolated using the Qiagen RNeasy kit following the 
manufacturers instructions.  
Liver RNA Isolation 
The same liver lobe was isolated from each mouse and stored in RNAlater 
(Qiagen) at -20°C indefinitely.  To isolate RNA, livers were homogenized using 7-9 2.0-
mm zirconium oxide Bullet Blender beads (Next Advance) in Trizol Reagent (Life 
Technologies) and the manufacturer’s instructions were followed.  After isolation, the 
RNA was cleaned using the RNeasy kit and stored at -80°C.   
 
Quantitative Real Time PCR 
Quantitative real time PCR (qRT-PCR) was performed on 100 ng of extracted 
RNA using a CFX96 Real-Time System (Bio-Rad) and TaqMan RNA-to-CT 1-step kit 
(Applied Biosystems).  Primer and probe sequences for SAA1, SAP, IL-6, TNFα, IL-1β, 
CXCL1, CXCL2, G-CSF, and 18s are listed in Table 2.  Probes were labeled on the 5’ 
end with FAM dye and Black Hole Quencher-1 at the 3’ end.  Each sample was 
normalized to 18s ribosomal RNA content and expressed as fold induction compared to 
uninfected mice, unless otherwise noted.  
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Table 2: Primer and Probe Sequences for qRT-PCR 





















































Single-Plex Enzyme-Linked Immunosorbent Assays (ELISAs) 
APP protein measurements were done by single-plex ELISAs.  SAA and SAP 
ELISAs were purchased from Immunology Consultants Laboratory, Inc.  Lipocalin-2 
(LCN2) and CRP DuoSet kits were purchased from R&D Systems, whereas LBP kits 
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were purchased from Cell Sciences, Inc.  The ELISAs were performed following the 
manufacturers’ instructions.   
Multi-Plex Bead Array 
Serum and BALF cytokine protein concentrations from each individual mouse 
were determined using a Bio-plex 200 workstation (Bio-Rad) in conjunction with a Bio-
plex cytokine bead array (Bio-Rad).  Included in the panel were IL-1β, IL-6, IL-10, IL-
17, G-CSF, GM-CSF, CXCL1, LIF, CXCL2 and TNFα.  The assay was performed 
following the manufacturer’s protocol. 
Bicinchoninic Acid (BCA) Assay  
 BALF total protein concentrations from each mouse were determined using the 
BCA assay (Sigma-Aldrich).  BSA was used as the protein standard at four different 
concentrations, 0, 0.2, 0.6, and 0.9 mg/ml, and the manufacturer’s instructions were 
followed to determine total protein concentrations of BALF as an index of pulmonary 
injury and of liver homogenates for immunoblots.   
 
Alanine Aminotransferase (ALT) Assay 
Serum ALT levels from individual mice were determined using Liquid ALT 
Reagent Set (Pointe Scientific, Inc.).  Serum was diluted 10-100 fold in saline and 100 µl 
was added to 1 ml of pre-warmed reagent.  Absorbance at 340 nm was read at minute 





Blood Urea Nitrogen (BUN) Assay 
BUN was measured in serum using the QuantiChrom Urea Assay Kit from 
BioAssay Systems following the manufacturers instructions. 
 
Western Blotting 
The same liver lobe from each mouse was isolated and homogenized in protein 
extraction buffer with 7-9 2.0-mm zirconium oxide beads (Next Advance) using the 
Bullet Blender.  Samples were then incubated on ice for 15 min with occasional 
vortexing to mix, followed by centrifugation for 20 min at 15,000 x g and 4°C to separate 
cellular debris.  The supernatants were aliquoted and stored at -80°C.  Total protein 
concentrations were measured by BCA assay as described above.  Immunoblotting was 
performed using the NuPAGE SDS polyacrylamide gel electrophoresis (PAGE) system 
(Novex, Life Technologies).  Samples were diluted to 20 µg of protein with NuPage 
lithium dodecyl sulfate sample buffer (Life Technologies), NuPage Reducing Agent (Life 
Technologies), and ultrapure water.  After boiling for 10 min at 70°C, 15 µl of diluted 
sample and Novex Sharp protein standard (Life Technologies) were loaded onto a 12% 
Bis-Tris gel (Life Technologies) in 1X 3-propansulfonic acid (MOPS) SDS running 
buffer and resolved at 200 V for 50 min or until the dye front was at the bottom of the 
gel.  Protein was then transferred onto an Immobilon-P, polyvinylidene fluoride (PVDF) 
membrane (Millipore) in 1X NuPage transfer buffer (Life Technologies) with 5% 
methanol at 30 V for one hour.  Following transfer, membranes were blocked in blocking 
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solution for one hour, rocking at room temperature.  After washing with TBS-T, the 
membrane was probed with a primary antibody (see Table 3 for a list of antibodies used, 
their concentrations and time of incubation).  After another wash in TBS-T, primary 
antibodies were detected using an anti-rabbit-HRP conjugated secondary antibody (Cell 
Signaling, #7074) at a 1:2000 dilution in blocking buffer.  Protein bands were then 
visualized using the ECLPlus Western Blotting Detection System (GE Healthcare).  
Membranes were exposed to film (GE Healthcare) for 0.5, 1, or 2 min.  Once bands were 
visualized, membranes were stripped of their antibodies using Re-Blot Plus Mild 
(Millipore) for 20 min, and then re-probed for loading controls as described above.  For 
cleaved caspase-3, densitometry was performed using ImageJ software (National 
Institutes of Health).  Densitometric values for each sample were normalized to its actin 
control band.  Cleaved-caspase 3:actin ratios were then compared to the 
HepSTAT3/RelA+/+/IgG control group to determine percent control changes in band 
intensity.  
 
Table 3: Primary Antibodies Used for Western Blotting 






Asp175, Clone 5A1E, 
#9664 
1:1000 Overnight at 4°C 





Liver Hematoxylin and Eosin (H & E) Staining 
Livers were isolated and immediately fixed in 10% buffered formalin (EMD 
Chemicals) indefinitely.  Once fixed, tissue sections were put into tissue cassettes and 
given to the Boston University School of Medicine Experimental Pathology Laboratory 
Service Core for processing. 
Paraffin Embedding for Immunohistochemistry 
 The same liver lobe was isolated from each mouse, cut into three sections, and 
immediately incubated in 50-ml conical tubes filled with 4% paraformaldehyde (PFA) in 
PBS overnight.  The next morning the PFA was poured off and livers were incubated in 
the specified solutions for the indicated times and temperatures in Table 4.  Surgipath 
Paraplast Plus paraffin (Leica Biosystems) was used in all of the embeddings (Fisher 
Scientific). After the last paraffin incubation in the vacuum, the tissue sections were put 
into 24 x 24 x 5 mm molds (Fisher Scientific), and cooled overnight at room temperature 
(RT) and then at 4°C to create the paraffin blocks.  Once cool, the blocks were sectioned 
into 5 µm thick sections using a microtome and adhered to microscope slides using a 







Table 4: Paraffin Embedding Protocol 
Solution Incubation Time Temperature 
PBS 30 min on ice 
0.85% NaCl 30 min on ice 
1:1 ethanol: 0.85% saline 30 min RT 
2X 70% ethanol 30 min each RT 
80% ethanol 45 min RT 
90% ethanol 46 min RT 
3X 100% ethanol 30 min each RT 
3X xylene 30 min each RT 
1:1 xylene: paraffin 1.5 h 60°C 
2X paraffin 1 h each 60°C vacuum 
 
Ki67 Immunohistochemistry on Liver Sections 
Following deparaffinization (see Table 5), liver sections were subjected to antigen 
retrieval by boiling samples in antigen unmasking solution (Vector) in a microwave for 3 
incubations of 5 min each at a low power.  After allowing the samples to cool for 30 min 
at RT in the same solution, slides were washed with PBS for 10 min and endogenous 
peroxidases were quenched with a 3% hydrogen peroxide solution in methanol (Fisher 
Scientific) for 15 minutes at RT.  Following another wash with PBS for 15 min, sections 
were blocked in a 1:200 dilution of normal donkey serum (Jackson ImmunoResearch 
Laboratories, Inc.) in PBS for 45 min at RT.  Sections were then stained for Ki67 
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overnight at 4°C using a primary, rabbit monoclonal, anti-Ki67 antibody (clone SP6, 
Abcam) at a 1:100 dilution in PBS.  The next day, following a 10 min wash in PBS, 
sections were incubated for 45 min at RT in a biotin-conjugated donkey anti-rabbit IgG 
secondary (Jackson ImmunoResearch Laboratories, Inc.) at a 1:200 dilution in PBS and 
then washed for another 10 min in PBS.  The secondary was then conjugated to HRP 
using the Vectastain ABC reagent kit (Vector) for 30 min at RT, washed for 10 min in 
PBS, and then developed with the DAB enzyme substrate kit (Vector).  Development 
time was kept standard for each sample (1 min).  The slides were then counterstained 
with hematoxylin, dehydrated by following Table 5 in reverse, and mounted with 
coverslips using Cytoseal XYL (Thermo Scientific).  Morphometric analysis was 
performed on stained sections by determining the number of cells positive for Ki67 per 
number of cells counted.  
 
Table 5: Deparaffinization Protocol 
Solution Incubation Time 
2X  Xylene 5 min each 
2X  100% Ethanol 2 min each 
90% Ethanol 1 min 
70% Ethanol 1 min 
50% Ethanol 1 min 





Fluorescence-Activated Cell Sorting (FACS) 
BALs were performed with ice-cold lavage buffer and heparinized blood was 
collected after 15 hours of infection with 4 x 105 CFU of E. coli.  BAL cells were pelleted 
after centrifugation for 5 min at 300 x g and 4°C followed by resuspension in 100 µl 
FACS buffer for staining.  Each blood sample was aliquoted into 2, 200-µl aliquots for 
red blood cell (RBC) lysis.  1 ml of 1X lysis buffer (BD Pharm Lyse, BD Biosciences) 
was added to each sample and incubated at RT for 2 min, with occasional vortexing.  Ten 
ml of PBS was then added to each sample to stop the lysing reaction, cells were pelleted 
by centrifugation for 5 min at 300 x g and 4°C, and then cells from the same samples 
were pooled and resuspended in 100 µl of FACS buffer for staining.  Surface antigens 
were stained by adding 20 µl of each diluted antibody (diluted in FACS buffer + FC 
Block [BD Biosciences]) from Table 6 to each sample.  After a 30 min incubation on ice 
and in the dark, the cells were washed by adding 4 ml of PBS to each tube, followed by 
pelleting by centrifugation.  Blood samples were resuspended in 200 µl of FACS buffer, 
while BALF samples were resuspended in 300 µl of FACS buffer for analysis.  Blood 
samples were sorted for circulating neutrophils and monocytes, and BAL samples were 
sorted for airspace neutrophils and airspace macrophages.  Surface markers for each cell 
type are listed in Table 7.  Single stained bead controls were utilized for gating and 
compensation, which was performed using the auto-compensation feature in the FACS 
Diva program that is used to operate the sorting machine.  Cells were sorted using the BD 
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FACS Aria into PBS containing 1% BSA, centrifuged at 300 x g for 5 min at 4°C and 
then resuspended in 1 ml of Trizol reagent.  RNA was isolated following the 
manufacturer’s protocol and qRT-PCR was performed as described above. 
 
Table 6: Antibodies Used for FACS Analysis 
Antibody Clone Fluorophore Dilution Company 
CD45 30-F11 PE-Cy7 1:1000 Biolegend 
Ly6G 1A8 APC-Cy7 1:800 Biolegend 
F4/80 CI:A3-1 Pacific Blue 1:50 Biolegend 
CD11b M1/70 APC 1:400 eBioscience 
CD115 AFS98 PE 1:200 Biolegend 
7AAD N/A N/A 5 ul /sample Biolegend 
 
Table 7: Cell Surface Markers Used for FACS Analysis 
Cell Type Surface Antigens 
Airspace Macrophage CD45+/7AAD-/F4/80+/Ly6G-/Autofluorescencehi 
Airspace Neutrophil CD45+/7AAD-/Ly6G+/F4/80- 
Circulating Monocyte CD45+/7AAD-/CD115+/CD11b+ 
Circulating Neutrophil CD45+/7AAD-/Ly6G+/ CD11b+ 	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BALF Neutrophil Live/Dead Gating 
Mice were infected for 15 hours with 4 x 105 CFU of E. coli, the lungs were 
lavaged with ice-cold lavage buffer, and cells were collected.  Cells were then stained for 
identification of BAL neutrophils as described in Table 6 and flow cytometry was 
performed as described above using the BD LSRII machine (BD Biosciences).  Dead 
neutrophil percentages were obtained by utilizing FlowJo to gate on 
CD45+/7AAD+/Ly6G+ cells in the BALF. 
pHrodo Phagocytosis Assay   
BALF cell phagocytosis was measured using red pHrodo E. coli bioparticles (Life 
Technologies), which fluoresce only in low pH environments (such as the 
phagolysosomal compartment).  Lyophilized pHrodo bioparticles were suspended in 250 
µl of PBS and sonicated for five minutes to create a single-particle suspension.  
HepSTAT3-/- and hepSTAT3+/+ mice were pretreated with 5 mg/kg of i.p. ultrapure LPS 
18 hours before i.t. infection with 106 CFU of E. coli.  Six hours after i.t. E. coli, mice 
were instilled with a 50 µl bolus of the pHrodo bioparticles and, after an hour incubation, 
the lungs were lavaged with ice-cold lavage buffer.  Cells were then stained to identify 
airspace neutrophils and macrophages as described above and analyzed using the LSRII 
flow cytometer.  Phagocytosis (PE fluorescence) was examined in each cell type using 





Figure 5. pHrodo Phagocytosis Assay Model   
HepSTAT3-/- and control hepSTAT3+/+ mice were pretreated with 5 mg/kg of ultrapure 
LPS intraperitoneally 18 hours prior to i.t. instillation of 106 CFU of E. coli.  After 6 
hours of E. coli infection, mice were instilled a second time with pHrodo bioparticles.  
An hour later, lungs were lavaged and phagocytosis was examined using flow cytometry. 
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ROS Generation Analysis 
Mice were treated with i.p. LPS for 18 hours, followed by i.t. E. coli (106 CFU).  Six 
hours after E. coli infection, the lungs were lavaged using ice-cold lavage buffer.  Using 
the CellROX Deep Red Reagent, BAL cells were stained for ROS generation at the same 
time as surface antigen staining (Life Technologies) with 5 µM of reagent for 30 min on 
ice.  Airspace neutrophils and macrophage ROS generation was analyzed using FlowJo. 
 
BALF Bacterial Growth Assay 
Luminescent E. coli Xen14 was diluted to 1x106 CFU/ml in PBS.  Cell-free 
BALF from mutant and hepSTAT3+/+ mice infected for 0, 6, or 24 hours after i.p. LPS 
pretreatment was aliquoted into a 96-well plate (90 µl/well) and then incubated with 10 µl 
of the bacterial suspension, resulting in an initial concentration of 1x105 CFU/ml in each 
well.  Before and after a 5 hour incubation rotating at 37°C, bacterial luminescence (as an 
indicator of bacterial growth) was measured using a luminometer (Turner BioSystems).  
Growth was calculated as fold increases based on the starting luminescent values.  No 
viable bacteria were detected from the aliquoted BALF. 
 
 Detection of NETs (MPO-DNA ELISA) 
A 96-well pate was coated with 5 µg/ml anti-MPO antibody (rabbit polyclonal, 
catalogue number ab9535, AbCam) overnight at 4°C, washed with PBS, and then 
blocked for 2 hours at room temperature with 5% BSA in PBS.  After washing with PBS, 
50 µl of cell-free BALF from hepSTAT3-/- and hepSTAT3+/+ mice infected for 0, 6, or 24 
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hours after LPS injection was added to the plate and incubated while shaking at room 
temperature for 2 hours.  After washing with wash buffer, a peroxidase-labeled anti-DNA 
monoclonal antibody, diluted 1:100 in 1% BSA in PBS (from Cell Death Detection 
ELISAPlus Kit, Roche, catalogue number 11774425001), was added and the plate was 
incubated for another 2 hours.  The wells were then washed with wash buffer and 100 µl 
of ABTS solution (also from Cell Death Detection ELISAPlus Kit) was added for 45 
minutes at room temperature in the dark.  The optical density of the plate was recorded at 
a wavelength of 405 nm.   
 
Serum Stimulation Assays 
Ex Vivo Serum Treatment Assay 
 Alveolar macrophages were collected by BAL from uninfected C57BL/6 mice.  
After lavaging with PBS, macrophages were pelleted after centrifugation for 5 min at 300 
x g and 4°C and washed twice in 1 ml of ice-cold, FBS-free RPMI media (with 1% Pen-
Strep).  Cells were then plated onto a 48-well plate at a concentration of 250,000 
cells/well and allowed to adhere for 1 hour at 37°C and 5% CO2.  After macrophages had 
adhered, RBCs and other non-adherent cells were washed away with 500 µl of complete 
RPMI media, and the macrophages rested overnight in complete RPMI media at 37°C 
and 5% CO2.  The next morning, cells were washed with PBS and then stimulated with 
either 100 ng/ml of ultrapure LPS or 105-102 CFU/ml of E. coli in the presence of 1% 
serum from either hepSTAT3/RelA+/+ or hepSTAT3/RelA-/- mice infected for 15 hours 
with 4 x 105 CFU of E. coli in antibiotic- (for E. coli stimulation only) and FBS-free 
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RPMI media.  LPS-stimulated cells were incubated for 4 hours.  For bacterial 
stimulations, E. coli were washed off with FBS-free RPMI media after 2 hours, and cells 
were cultured for another 2 hours in media containing the same 1% serum from mice as 
described above.  RNA was then collected by removing the media, aliquoting 1 ml of 
Trizol directly into each well, and pipetting up and down to release and lyse the cells.  
RNA isolation was performed according to Trizol’s instructions and stored at -80°C.  
qRT-PCR was performed and expression of IL-6, TNFα, and CXCL1 were analyzed. 
 
Buffer Recipes 
Lavage Buffer for BAL Cell Collection 
2.7 mM Ethylenediaminetetraacetic acid (EDTA), 20 mM 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic Acid (HEPES), and 100 U/ml Penicillin-
Streptomycin (Pen-Strep) in Hanks Balanced Salt Solution (HBSS) –This buffer was 
used instead of PBS as indicated.  
Protein Extraction Buffer 
25 mM Tris at pH 7.4, 50 mM Sodium Chloride, 0.5% Sodium Deoxycholate, 2% NP-40, 
0.2% Sodium Dodecyl Sulfate (SDS), and 1x Roche Complete Protease Inhibitor in 
deionized water  
Tris Buffered Saline-Tween (TBS-T) 




5% Non-Fat Milk in TBS-T 
Fluorescence-Activated Cell Sorting (FACS) Buffer 
0.5% Fetal Bovine Serum (FBS) and 2 mM EDTA in PBS – Filter Sterilized 
MPO-DNA ELISA Wash Buffer 
1% Bovine Serum Albumin (BSA) and 0.05% Tween-20 in PBS 
Roswell Park Memorial Institute (RPMI) Complete Media 
10% FBS and 1% Pen-Strep in RPMI (with L-glutamine) –Filter Sterilized 
 
Statistical Analysis 
All statistical analyses were done using GraphPad Prism 6.0 (GraphPad).  CFU 
data are illustrated as individual values with medians, whereas the remaining data are 
shown as means ± SEM.  Two groups were compared using either a student’s t test or a 
Mann-Whitney test, while multiple group comparisons were conducted using either a 
one- or two-way analysis of variance (ANOVA), followed by specific post hoc tests 
(Dunn’s test for multiple comparisons or the Holm-Sidak test).  Data were considered 





CHAPTER THREE: THE ACUTE PHASE RESPONSE FACILITATES MOUSE 
SURVIVAL, HEPATOPROTECTION, AND PULMONARY INFLAMMATION 
DURING E. COLI PNEUMONIA  
Parts of this chapter were originally published in: Hilliard, K.L., E. Allen, K.E. 
Traber, K. Yamamoto, N.M. Stauffer, G.A. Wasserman, M.R. Jones, J.P. Mizgerd, and 
L.J. Quinton. The Lung-Liver Axis Facilitates Pulmonary Innate Immunity and 
Hepatoprotection during Pneumonia. The American Journal of Respiratory Cell and 
Molecular Biology. 2015. Epub ahead of print. Copyright 2015 by The American 





The hepatic APR is stimulated by inflammation or injury, including pneumonia 
(Gabay and Kushner, 1999; Quinton et al., 2012a; Quinton et al., 2009), and is defined as 
a significant change in the circulating concentrations of the various APPs.  Each APP has 
a specific function, but the wholesale function of the APR has yet to be elucidated, 
especially during lung infections (Gabay and Kushner, 1999; Moshage, 1997; Suffredini 
et al., 1999).  Upon entrance into the lungs, microbial killing is mediated by the innate 
inflammatory response.  This complex response is largely mediated by cytokine 
production and leukocyte recruitment.  Proper immune activation required for pathogen 
clearance, however, can result in ALI by compromising epithelial barrier integrity, thus 
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allowing for plasma protein (and perhaps APP) extravasation into the airspaces (Mizgerd, 
2008).   
Previous work from our laboratory has shown that critical pulmonary host defense 
cytokines, IL-6, TNFα, and IL-1, are necessary for APR induction during bacterial 
pneumonia, suggesting a lung-liver axis that promotes innate immunity (Quinton et al., 
2009).  Furthermore, hepatic STAT3 and NF-κB RelA transcription factor activation, 
which is necessary for APP expression, was dependent on these cytokine pathways 
(Quinton et al., 2012a; Quinton et al., 2009; Quinton et al., 2008).  Based on these 
findings, our laboratory generated an APR-null mouse model in which hepatocyte 
STAT3 and RelA were specifically deleted.  These mice are phenotypically normal under 
resting conditions, but after infection display an ablated APR (Quinton et al., 2012a).  
Previous studies using this model of APR deficiency showed the necessity of the APR for 
systemic host defense during a Gram-positive pneumonia (Quinton et al., 2012a).  While 
these studies show an important function of the APR as a whole, they were not 
empowered to determine the role of the APR in lung inflammation due to the high 
virulence of the pneumococcal strain used (serotype 3).  In this aim, we utilized distinct 
inocula of E. coli to precisely and comprehensively determine how the APR affects lung 





3.1 The APR is necessary for survival during pneumonia. 
To determine the role of liver-specific acute phase changes in response to Gram-
negative bacterial lung infections, we used our previously established mouse model in 
which Cre-recombinase under transcriptional control of an albumin promoter drives the 
deletion of floxed STAT3 and RelA alleles (Quinton et al., 2012a).  This strategy severs 
the lung-liver axis, ablating gene expression changes in response to all conditions so far 
tested (Quinton et al., 2012a).  HepSTAT3/RelA-/- or control hepSTAT3/RelA+/+ mice 
were infected intratracheally with 106 CFU of E. coli, strain O6:K2:H1.  E. coli is 
amongst several species of Gram-negative enterobacteria that are common and relevant 
causes of nosocomial pneumonia (Ahmed and Niederman, 2001; El Solh et al., 2007; 
Jones, 2010).  Additionally, E. coli is a well-established model of Gram-negative lung 
infections in mice (Balamayooran et al., 2012; Mei et al., 2010; Quinton et al., 2008; 
Yamada et al., 2011), and was particularly desirable in our current study due to its ability 
to be consistently titrated to cause varying degrees of inflammation.  E. coli causes a self-
resolving or severe pneumonia, depending on dose, that causes little to no systemic 
dissemination and can also elicit significant airspace edema.  All of which enable us to 
effectively study the influence of exudate APPs on localized lung inflammation and host 
defense without the potentially confounding effects of disseminated bacteria on liver 
stimulation.  Of particular importance to this study is our previous finding that E. coli 
pneumonia induces a robust liver response that occurs independently of dissemination, 
and is instead dependent on signaling from IL-6, TNFα, and IL-1 (Quinton et al., 2009).  
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After infection, we observed that hepSTAT3/RelA-/- mice succumbed to the infection at a 
significantly greater rate than their littermate controls, indicating that hepatic 
transcription is necessary for survival following what is revealed here as a severe and 
lethal E. coli infection in mutant mice (Figure 6).   
 
3.2 The APR is Dependent on Hepatic STAT3 and RelA Activation 
In order to determine the direct relationship between survival and the pneumonia-
induced APR, we measured liver mRNA induction (Figure 7) and circulating 
concentrations (Figure 8) of five representative APPs: SAA, SAP, LBP, CRP, and LCN2.  
As anticipated, hepSTAT3/RelA+/+ mice had a large APP response (liver mRNA and 
circulating protein) that was completely ablated in hepSTAT3/RelA-/- mice, suggesting 
that the APR is dependent on hepatocyte STAT3 and RelA activation during E. coli 
pneumonia, consistent with studies already published (Quinton et al., 2012a). 
We next sought to determine the ability of APPs to extravasate into infected 
airspaces where they would be positioned to directly modulate inflammation and host 
defense, possibly contributing to lethality in hepSTAT3/RelA-/- mice.  To this end, BALF 
protein levels of all APPs measured were markedly elevated in response to infection in 
control hepSTAT3/RelA+/+ mice (Figure 9).  As observed in the circulation, SAA protein 
concentrations were significantly reduced in hepSTAT3/RelA-/- mice (Figure 9A).  Lung 
mRNA induction of SAA1 was unaffected by genotype (Figure 10A), suggesting that 
differences in BALF protein concentrations were likely due to differences in delivery 




Figure 6. The APR is necessary for survival during a high inoculum E. coli 
pneumonia.  
HepSTAT3/RelA-/- and control hepSTAT3/RelA+/+ mice were infected intratracheally 
with 1 x 106 CFU of E. coli.  Survival was observed and significance was assessed with a 
Mantel-Cox test.  The two curves were deemed significant if p < 0.05 (n = 33 





Figure 7. Liver expression of APPs during a high inoculum E. coli pneumonia is 
dependent on hepatic STAT3 and RelA.  
Control hepSTAT3/RelA+/+ and hepSTAT3/RelA-/- mice were infected intratracheally 
with 1 x 106 CFU of E. coli.  At the indicated time points, the liver was homogenized and 
RNA was extracted.  Induction of SAA1, SAP, and LBP was analyzed by qRT-PCR.   
*p < 0.05 for overall effect of genotype as determined by 2-way ANOVA. # p < 0.05 vs 
hepSTAT3/RelA+/+ mice at the indicated time point as determined by a Holm-Sidak post 




Figure 8. Liver STAT3 and RelA are necessary for induction of circulating APP 
concentrations during a high inoculum E. coli pneumonia.  
Control hepSTAT3/RelA+/+ and hepSTAT3/RelA-/- mice were infected intratracheally 
with 1 x 106 CFU of E. coli.  At the indicated time points, serum was collected and APP 
concentrations were determined by ELISA.  *p < 0.05 for overall effect of genotype as 
determined by 2-way ANOVA.  # p < 0.05 vs hepSTAT3/RelA+/+ mice at the indicated 




Figure 9. Intrapulmonary APP content is influenced by systemic acute phase 
changes. 
HepSTAT3/RelA-/- and control hepSTAT3/RelA+/+ mice were intratracheally inoculated 
with 1x106 CFU of E. coli.  At the indicated time points, the lungs were lavaged with 
PBS and BALF was collected.  APP concentrations in the BALF were measured by 
ELISA.  * p < 0.05 for overall effect of genotype as determined by 2-way ANOVA. # p < 
0.05 vs hepSTAT3/RelA+/+ mice at the indicated time point as determined by a Holm-




Figure 10. The systemic APR does not mediate pulmonary APP transcript 
expression.  
HepSTAT3/RelA-/- and control hepSTAT3/RelA+/+ mice were intratracheally inoculated 
with 1x106 CFU of E. coli, and the infected, lavaged (left) lobe was homogenized.  RNA 
was isolated and APP transcript expression was determined using qRT-PCR (n = 3-8 per 
group).  Significance was assessed by 2-way ANOVA. # p < 0.05 vs hepSTAT3/RelA+/+ 
mice at the indicated time point as determined by a Holm-Sidak post hoc test. 
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This was further evidenced by a direct correlation between BALF and serum SAA 
concentrations after 30 hours of infection (Figure 11A).  The remaining APPs measured 
(SAP, LBP, CRP, and LCN2), however, showed no difference in airspace protein levels 
between genotypes (Figure 9B-E), nor was the correlation between BALF and serum 
SAP, LBP, CRP, or LCN2 concentrations significant (Figure 11B-E), indicating that lung 
APP content is only selectively dependent on hepatic responses following a high 
inoculum E. coli pneumonia.   
 
3.3 The APR promotes maximal pulmonary bacterial clearance during a lethal E. coli 
pneumonia. 
In order to determine if the APR affects lung inflammation, BALF total protein 
concentrations (Figure 12A) and recruited neutrophil numbers (Figure 12B) were 
determined.  In both genotypes, the effect of pneumonia was substantial yet equivalent, 
suggesting that mortality in hepSTAT3/RelA-/- mice is not directly attributable to changes 
in acute pulmonary inflammation.  However, there was a significant increase in 
pulmonary bacterial burdens in hepSTAT3/RelA-/- mice after 30 hours of infection 
(Figure 12C).  This defect on pulmonary host defense did not translate to systemic 
defects, as blood bacterial burdens were equivalent in both genotypes (Figure 12D).  Due 
to a potential survival bias, bacterial burdens were not measured at later time points.  
Nevertheless, increased pulmonary bacterial burdens in hepSTAT3/RelA-/- mice indicate 




















Figure 11. Intrapulmonary concentrations for select APPs significantly correlate 
with systemic levels.   
A correlation with a linear regression was performed comparing serum (from Figure 8) 
and BALF APP concentrations (from Figure 9).  Individual values represent those 




Figure 12. The APR is required for maximal pulmonary host defense.   
Mice were infected intratracheally with 1 x 106 CFU of E. coli.  At indicated time points, 
the lungs were lavaged and BALF was collected.  (A) Total protein was measured by 
BCA assay and (B) recruited neutrophils were counted as indexes of pulmonary 
inflammation and injury.  Significance was assessed by 2-way ANOVA (n = 4-8 per 
group).  C, D) After 30 hours of infection, lung homogenates and heparinized blood were 
serially diluted and plated on blood agar plates.  After an overnight incubation at 37°C, 
colonies were counted and bacterial burdens were expressed as CFU per lung or milliliter 
of blood.  *p < 0.05 vs. control hepSTAT3/RelA+/+ mice as determined by a student’s t 
test.   
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3.4 APR deficiency causes liver injury in lethally challenged mice. 
Although hepSTAT3/RelA-/- mice have significantly increased lung bacterial 
burdens, the observed increase is relatively modest, warranting further investigation into 
the potential cause of death in mice lacking a hepatic APR.  It has been shown that NF-
κB RelA deficiency results in embryonic lethality due to liver degeneration and 
hepatotoxicity (Alcamo et al., 2001; Beg and Baltimore, 1996; Beg et al., 1995; Dou et 
al., 2012; Tanaka et al., 1999).  Targeted disruption of RelA in the liver also causes 
hepatotoxicity in direct response to systemic TNF or LPS, but the importance of 
inducible RelA (i.e. that observed during the APR) has never been explored in the context 
of lung infections.  We hypothesized that pneumonia-induced mortality is attributable, at 
least in part, to liver injury in hepSTAT3/RelA-/- mice, which lack both RelA and 
STAT3.  To test this, we measured serum ALT levels as a sensitive metric of 
hepatotoxicity.  While pneumonia had no effect on liver injury in hepSTAT3/RelA+/+ 
mice, hepSTAT3/RelA-/- mice had significantly increased levels of serum ALT over the 
course of infection (Figure 13A).  This finding was confirmed by histological evidence of 
hepatocyte death in the absence of STAT3 and RelA (Figure 14).  Interestingly, liver 
TNFα mRNA induction was significantly, albeit modestly, higher in hepSTAT3/RelA-/- 
mice (Figure 13B).  This finding suggests a cycle whereby both the expression of and 
response to TNFα is altered in hepSTAT3/RelA-/- mice, resulting in liver damage and 
toxicity.  However, the observed difference in TNFα mRNA was not sufficient to 
manifest in circulating TNFα protein changes in the same mice (Figure 13C), making the 




Figure 13. APR-null mice have severe liver injury. 
HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were infected with 1x106 CFU of E. 
coli.  At indicated time points, serum and livers were collected.  A) Serum ALT levels 
were measured via colorimetric assay.  B) Livers were homogenized and RNA was 
isolated.  TNFα mRNA transcript induction was measured by qRT-PCR.  C) Serum 
concentrations of TNFα were determined by multiplex bead array.  *p < 0.05 for overall 
effect of genotype as determined by 2-way ANOVA.  # p < 0.05 vs hepSTAT3/RelA+/+ 






Figure 14.  HepSTAT3/RelA-/- mice have liver injury that is TNFα-dependent.  
Mice were injected intravenously by tail vein with 5 mg/ml of either a control IgG or 
anti-TNFα antibody, followed immediately by i.t. E. coli (1x106 CFU).  After 24 hours of 
infection, histopathology was assessed by H&E stained liver sections.  Black arrows 
indicate areas of acute liver injury.  Representative sections were compared between 3 
mice per group and were viewed at 20x magnification.   
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3.5 Liver injury in HepSTAT3/RelA-/- mice is TNFα-dependent. 
To determine if this injury was dependent on TNFα, which has previously been 
linked to hepatotoxicity in absence of RelA (Alcamo et al., 2001; Beg et al., 1995; Ding 
and Yin, 2004; Doi et al., 1999; Li et al., 1999), we treated mice with 5 mg/ml of either a 
neutralizing TNFα or IgG control antibody by tail vein injection immediately prior to i.t. 
E. coli.  As expected, at 24 hours post infection, hepSTAT3/RelA-/- mice treated with the 
control IgG antibody had high levels of circulating ALT (Figure 15A), consistent with 
our initial results (Figure 13A).  In contrast, hepSTAT3/RelA-/- mice treated with an anti-
TNFα antibody had serum ALT concentrations that were identical to baseline levels 
observed in hepSTAT3/RelA+/+ mice (Figure 15A).  Histology also confirmed the 
protective effect of the neutralizing TNFα antibody, with histopathology far more 
reflective of hepSTAT3/RelA+/+ mice than that of untreated hepSTAT3/RelA-/- 
littermates (Figure 14).  Lung and blood bacterial burdens were also measured at 24 
hours post infection to confirm that the anti-TNFα antibody had no adverse effects on 
host defense, which would confound interpretations of host outcomes (Figure 15B).  As 
expected, the effect of genotype on bacterial killing was similar to that observed at 30 
hours post infection (Figure 12C), but this outcome was unaffected by TNFα 





Figure 15. Hepatotoxicity during a high inoculum E. coli pneumonia is TNFα-
dependent. 
In order to determine the influence of TNFα on liver injury, mice were injected 
intravenously by tail vein with 5 mg/ml of either a control IgG or anti-TNFα antibody, 
followed immediately by i.t. E. coli (1x106 CFU).  A) Serum ALT levels were 
determined 24 hours post infection as an indicator of the amount of liver injury present.  
*p < 0.05 vs. hepSTAT3/RelA+/+/IgG control group was determined by a one-way 
ANOVA followed by a Holm Sidak test (n = 3-13 per group).  B) Lung homogenates 
were serially diluted and plated on blood agar plates and bacterial burdens were 
determined.  *p < 0.05 for overall effect of genotype as determined by 2-way ANOVA (n 
= 3-6 per group).  
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3.6 Liver injury in APR-deficient mice is associated with increased hepatic apoptosis. 
To determine whether liver injury was specifically linked to apoptosis in APR-
null, hepSTAT3/RelA-/- mice, we determined protein levels of cleaved caspase-3, the 
effector caspase for the apoptotic pathway, via immunoblot of liver homogenates 24 
hours after i.t. E. coli (Figure 16A).  Densitometric analysis of immunoblots revealed 
significantly higher levels of cleaved caspase-3 in the absence of hepatocyte STAT3 and 
RelA that were almost completely reversed with TNFα neutralization (Figure 16B), 
suggesting that liver injury was at least partly attributable to TNF-induced apoptosis.  
These data are consistent with previous reports indicating RelA-mediated protection from 
TNF-induced liver apoptosis (Alcamo et al., 2001). 
3.7 Liver cellular repair is not affected by hepSTAT3/RelA deletion. 
In addition to hepatocyte loss (i.e. injury), hepatocyte replacement could also be 
compromised in APR-null mice, as supported by studies showing STAT3-dependent liver 
regeneration (Ding and Yin, 2004; Doi et al., 1999; Li et al., 2002).  To address this, we 
stained liver sections for Ki67, a nuclear antigen used to detect proliferating cells (Figure 
17A).  As expected, we observed few positively stained cells in the hepSTAT3/RelA+/+ 
control group 24 hours after i.t. E. coli, but there was a marked increase in the percentage 
of Ki67+ cells in IgG treated hepSTAT3/RelA-/- mice that was partially reversed upon 
TNFα neutralization (Figure 17B).  Thus, these data do not support a defect in hepatocyte 
turnover as a cause of liver injury in hepSTAT3/RelA-/- mice.  Rather, cell proliferation 
appeared to be downstream of hepatotoxicity, with the greatest amounts of Ki67 staining 




Figure 16.  HepSTAT3/RelA-/- mice have increased hepatic apoptosis during a high 
inoculum E. coli pneumonia. 
HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were injected intravenously by tail vein 
with 5 mg/ml of either a control IgG or anti-TNFα antibody, followed immediately by i.t. 
E. coli (1x106 CFU).  A) After 24 hours of infection, protein was extracted from liver 
homogenates and subjected to immunoblot analysis for cleaved caspase-3 expression.  
Each band represents data from an individual mouse.  One of two representative blots 
with livers from four independent experiments is shown.  B) A densitometric analysis of 
band intensity was performed on the immunoblots.  The ratio of cleaved caspase-3/pan 
actin was compared to the hepSTAT3/RelA+/+/IgG control group for each sample to 
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calculate the percent control changes in band intensity ratios.  *p < 0.05 vs. 
hepSTAT3/RelA+/+/IgG group was determined by a one-way ANOVA followed by a 




Figure 17.  The APR does not affect liver repair during a high inoculum pneumonia.  
Mice were injected intravenously by tail vein with 5 mg/ml of either a control IgG or 
anti-TNFα antibody, followed immediately by i.t. E. coli (1x106 CFU).  A) After 24 
hours of infection, cell turnover, as a marker of liver repair, was assessed by 
immunohistochemical staining for Ki67.  Black arrows indicate areas of acute liver injury 
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(top panels) or a Ki67+ cell (bottom panels).  Representative images are shown for livers 
collected from at least 3 individual mice per group at 20X magnification.  B) A blinded 
morphometric analysis was performed on liver sections stained for Ki67 from panel A.  
Data are expressed as the percentage of all cells that stained positively for Ki67.  *p < 
0.05 vs. hepSTAT3/RelA+/+/IgG control group was determined by a one-way ANOVA 
followed by a Holm Sidak test (n = sections from 3 mice per group, with at least 6 fields 
of view analyzed).  
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3.8 Hepatotoxicity is the not sole cause of mortality in APR-deficient mice during E. coli 
pneumonia. 
To determine whether liver injury was the sole cause of mortality in 
hepSTAT3/RelA-/- mice, we measured survival in APR-null mice treated with either the 
control or αTNF antibody, the latter of which reversed all metrics of hepatotoxicity.  
Surprisingly, hepSTAT3/RelA-/- mice treated with the neutralizing TNFα antibody, 
which had normal liver function and baseline levels of hepatic injury, exhibited no 
improvement in survival (Figure 18A), suggesting that the physiological significance of 
the APR extends beyond inducible hepatoprotection.  As another insight into the potential 
cause of mortality in the APR-null mice, we measured BUN levels as an indicator of 
kidney function, and there were no differences between genotypes (Figure 18B).  The 
mechanism by which the APR prevents mortality during a severe pneumonia remains 
unknown. 
 
3. 9 Liver-derived proteins are necessary to promote pulmonary inflammation during a 
low inoculum (non-lethal) E. coli pneumonia. 
Due to lethality differences and a potential survival bias introduced to the results 
described above, we inoculated mice with a milder dose of E. coli (4 x 105 CFU) to more 
carefully determine the impact of liver acute phase changes on lung inflammation and 
host defense.  At this dose, we observed only rare mortality with no significant difference 




Figure 18. Reversal of liver injury does not improve survival in APR-deficient, 
hepSTAT3/RelA-/- mice during a high inoculum E. coli pneumonia. 
A) HepSTAT3/RelA-/- mice were infected intratracheally with 1x106 CFU of E. coli 
immediately following i.v. injection of 5 mg/ml of a control IgG or neutralizing TNFα 
antibody.  Survival was observed through 48 hours of infection.  A Mantel-Cox test was 
used to determine significance (n = 4-5 per group).  B) HepSTAT3/RelA+/+ and 
hepSTAT3/RelA-/- mice were infected with i.t. E. coli (1 x 106 CFU).  At the indicated 
time points, blood was collected and serum was isolated.  BUN was determined using a 
colorimetric assay as a determinate of kidney function.  Significance was assessed by 2-
way ANOVA (n = 4-9 per group).   
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The magnitude of the APR itself, as determined by systemic SAA and SAP expression 
(liver mRNA and circulating protein content), was much milder in response to the non-
lethal challenge compared to that described above, and remained blunted in 
hepSTAT3/RelA-/- mice (Figures 19A-D).  We also observed an increase in airspace SAA 
and SAP concentrations in hepSTAT3/RelA+/+ mice that was completely absent in 
hepSTAT3/RelA-/- mice (Figure 20A, B).  Again, this disparity between genotypes was 
not due to differential local expression of these proteins, as there was no significant 
decrease in lung mRNA induction between genotypes (Figure 20C, D).   
 In association with decreased APP levels, we also observed significantly reduced 
total protein concentrations and a trend towards less neutrophil recruitment in the BALF 
of hepSTAT3/RelA-/- mice (Figures 21A, B).  This possible decrease in airspace 
neutrophil numbers was not due to greater cell death, as 7AAD+ (dead) neutrophil 
percentages were unchanged in BALF from hepSTAT3/RelA-/- mice 15h after i.t. E. coli 
(Figure 21C).  Lung bacteria were virtually cleared by 30 hours of infection in response 
to this milder inoculum, with no difference observed between genotypes (Figure 22A).  
Additionally, there was no observable bacteremia through 30 hours for either group 
(Figure 22B).  In accordance with decreased pulmonary inflammation, the majority of 
cytokines measured (IL-6, G-CSF, CXCL1, TNFα, CXCL2, IL-10 and LIF) were 
significantly decreased in hepSTAT3/RelA-/- mice compared to hepSTAT3/RelA+/+ mice 




Figure 19. Low inoculum infected mice have an impaired APR. 
HepSTAT3/RelA+/+ or hepSTAT3/RelA-/- mice were instilled intratracheally with 4x105 
CFU of E. coli.  A, B) At the indicated time points, liver mRNA was extracted and SAA1 
and SAP transcript fold induction was determined using qRT-PCR.  C, D) Serum was 
collected and concentrations of SAA and SAP were determined by ELISA.  *p < 0.05 for 
overall effect of genotype over the indicated time course as determined by 2-way 
ANOVA.  # p < 0.05 vs hepSTAT3/RelA+/+ mice at the indicated time point as 




Figure 20. Intrapulmonary APP concentrations are decreased after a low inoculum 
E. coli pneumonia. 
HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were infected with 4x105 CFU of E. 
coli and lungs were lavaged at the indicated time points with PBS.  A, B) BALF SAA 
and SAP concentrations were determined by ELISA.  C, D) Lavaged, infected (left) lobes 
were homogenized and RNA was extracted.  SAA1 and SAP transcript fold inductions 
were determined using qRT-PCR.  *p < 0.05 for overall effect of genotype as determined 
by 2-way ANOVA.  # p < 0.05 vs hepSTAT3/RelA+/+ mice at the indicated time point as 






Figure 21.  The APR facilitates pulmonary inflammation during a low inoculum E. 
coli pneumonia. 
 HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were infected with 4x105 CFU of E. 
coli and lungs were lavaged at the indicated time points with PBS.  (A) BALF total 
protein concentrations were measured by BCA assay and (B) total BALF neutrophils 
were enumerated. *p < 0.05 for overall effect of genotype as determined by 2-way 
ANOVA.  # p < 0.05 vs hepSTAT3/RelA+/+ mice at the indicated time point as 
determined by a Holm-Sidak post hoc test (n = 5-11 per group).  C) After 15 hours of 
infection with 4 x 105 CUF of E. coli, cells from the BALF were collected and stained for 
total (CD45+/Ly6G+) or dead (CD45+/7AAD+/Ly6G+) neutrophils.  Percentages of dead 
neutrophils are calculated from total numbers of neutrophils.  Significance vs. 




Figure 22. Pulmonary bacterial clearance is not impaired in hepSTAT3/RelA-/- mice 
during a low inoculum E. coli infection.  
HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were infected intratracheally with 4x105 
CFU of E. coli. After 15 or 30 hours of infection, lung homogenates and heparinized 
blood were serially diluted and plated on blood agar plates.  The lowest dilution utilized 
is indicated as the limit of detection in each panel.  After an overnight incubation at 37°C, 
colonies were counted, and bacterial burdens were expressed as CFU per lung or 




Figure 23.  Pulmonary cytokine production during a low inoculum E. coli 
pneumonia is mediated by the hepatic APR.  
HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were infected intratracheally with 4x105 
CFU of E. coli. A) At 15 hours post infection, BALF cytokine protein concentrations 
were measured by a multiplex bead array (Luminex).  B) At the same time point, lavaged, 
infected (left) lobes were homogenized, RNA was extracted, and cytokine mRNA 
induction was measured by qRT-PCR.  *p < 0.05 vs. hepSTAT3/RelA+/+ mice, assessed 
by Student t test (n = 10-11 per group).  
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Specific inflammatory cytokines were decreased by at least 50%, some greater, indicating 
that the APR induces a biologically relevant change in pulmonary inflammation.  mRNA 
induction of IL-6, TNFα, CXCL2, CXCL1 and G-CSF were also measured in lung 
homogenates (Figure 23B).  Despite the fact that only IL-6 and CXCL1 were 
significantly decreased in hepSTAT3/RelA-/- mice, CXCL2 and G-CSF also trended 
toward decreased in hepSTAT3/RelA-/- mice, corroborating airspace protein levels.  
While cytokines known to be downstream of IL-17 during pneumonia (e.g. CXCL1/2 and 
G-CSF) (Ye et al., 2001) were decreased in mutant mice, IL-17 itself remained 
unchanged (Figure 23A), supporting the observed phenotype as a Th17-independent 
phenomenon.  These data indicate that the hepatic transcriptional responses facilitate 
acute pulmonary inflammation, as revealed by a milder, nonlethal pneumonia.   
 
3.10 The liver APR facilitates cytokine expression through airspace macrophages. 
 The data above suggest that liver-derived APPs enhance immune responsiveness, 
demanding a more complete understanding of where this process occurs. For instance, it 
is plausible that products downstream of the liver APR act upon circulating cells in the 
blood, recruited and/or resident cells in the infected airspaces, or perhaps both.  In order 
to determine the effect of the APR on cytokine expression in circulating, recruited, and 
lung-resident myeloid-derived leukocytes, we used FACS to isolate cells from blood and 




Figure 24. Airspace and circulating cell sorting workflow.  
HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were infected for 0, 1.5, or 15 hours 
with 4x105 CFU of E. coli.  Lungs were lavaged, blood was collected, and RBCs were 
lysed.  Cells were collected and stained for FACS using the cell surface markers shown 
above.  After individual cell type separation, RNA was isolated and cytokine induction 
was determined by qRT-PCR. 
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Both circulating monocytes (CD45+/7AAD-/CD115+/CD11b+) (Hanna et al., 2011) and 
neutrophils (CD45+/7AAD-/Ly6G+/ CD11b+) showed no differences in cytokine 
induction between genotypes at 15 hours post infection (Figure 25B, C).  In these cells, 
cytokine expression varied from undetectable (monocyte CXCL1), to increased 
(monocyte IL-6 and IL-1β; neutrophil CXCL1), to decreased (neutrophil IL-1β).  In 
contrast, induction of IL-6 and CXCL1 in airspace macrophages (CD45+/7AAD-
/F4/80+/Ly6G-) from hepSTAT3/RelA-/- mice was significantly decreased after 15 hours 
of infection compared to macrophages from hepSTAT3/RelA+/+ mice (Figure 26B).  
Induction of IL-1β was unaffected, which was consistent with unchanged BALF protein 
concentrations (Figures 26B and 23A).  This cytokine induction phenotype was unique to 
airspace macrophages, as airspace neutrophils (CD45+/7AAD-/Ly6G+/F4/80-) showed no 
differences in gene expression for the cytokines measured (Figure 26C).  To determine if 
the changes in cytokine induction required APP delivery into the airspaces (via serum 
extravasation), we measured cytokine induction at 1.5 hours post infection, a time 
preceding loss of alveolar barrier integrity, and thus serum protein (and APP) 
extravasation.  Cytokine mRNA was induced, but was equivalent between genotypes at 
this early point of infection (Figure 26B), suggesting that changes in cytokines are not 
intrinsic to local cells, but rather, are due to differences in APP exposure from 
extravasated serum.  Taken together, the data imply a role for airspace macrophage 





Figure 25. Cytokine induction in circulating cells is not affected by the APR.  
HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were infected for 0, 1.5, or 15 hours 
with 4x105 CFU of E. coli.  Blood was collected, RBCs were lysed, and cells were 
stained for FACS.  A) Representative dot plot are shown. Circulating monocytes were 
gated on CD45+/7AAD-/CD115+/CD11b+ and circulating neutrophils were gated on 
CD45+/7AAD-/Ly6G+/ CD11b+.  RNA was extracted and qRT-PCR was performed to 
determine induction of IL-6, CXCL1 and IL-1β in both circulating monocytes (B) and 
neutrophils (C).  The overall effect of genotype was determined by 2-way ANOVA (n = 




Figure 26. Airspace macrophages are responsible for APP-induced cytokine changes 
in low inoculum infected mice. 
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HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were infected for 0, 1.5, or 15 hours 
with 4x105 CFU of E. coli.  Lungs were lavaged, and cells were collected and stained for 
FACS.  A) Airspace macrophages were gated on CD45+/7AAD-/F4/80+/Ly6G- and 
airspace neutrophils were gated on CD45+/7AAD-/Ly6G+/F4/80-.  RNA was extracted 
and qRT-PCR was performed to determine induction of IL-6, CXCL1 and IL-1β in 
airspace macrophages (B) and determine expression of IL-6, CXCL1 and IL-1β relative 
hepSTAT3/RelA+/+ controls in airspace neutrophils (C), as there is no recruitment of 
neutrophils to the airspaces at baseline or 1.5 hours after infection.  For panel B, *p < 
0.05 for overall effect of genotype or vs. control mice in the same group as determined by 
2-way ANOVA followed by Holm Sidak test (n = 3-6 per group).  For panel C, 
significance was assessed by student t test (n = 10-11 per group). 
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3.11 Serum components do not directly modulate cytokine expression ex vivo. 
 The above data suggest that the hepatic APR promotes cytokine induction, 
specifically in airspace macrophages.  We sought to develop an ex vivo system to test if 
serum components, including APPs, could directly modulate cytokine production in 
primary alveolar macrophages after ex vivo stimulation with LPS (Figure 27).  In order to 
determine the dose of LPS most effective in activating the cells and inducing cytokine 
expression, we stimulated primary alveolar macrophages from C57BL/6 mice with 
varying doses of LPS for four hours.  After stimulation, RNA was isolated and IL-6 
expression was determined using qRT-PCR (Figure 28A).  IL-6 production was greatest 
at the lowest concentration of LPS (100 ng/ml).  Macrophages were then stimulated in 
the presence of varying concentrations of serum from hepSTAT3/RelA+/+ mice infected 
for 15 hours with 4 x 105 CFU of E. coli.  Mouse serum had a generally repressive effect, 
as the higher percentages of serum used resulted in the lowest cytokine expression 
compared to cells stimulated in the presence of FBS (Figure 28B).  Because of this, we 
used 1% serum in all stimulations so that changes in cytokine expression could be 
observed.  Following protocol optimization, we stimulated primary alveolar macrophages 
with 100 ng/ml of LPS in the presence of serum from uninfected or 15 hour, mildly 
infected hepSTAT3/RelA-/- or hepSTAT3/RelA+/+ mice.  Expression of both IL-6 and 
TNFα were unchanged due to serum source, as neither infection status nor genotype of 





Figure 27. Ex vivo LPS and serum stimulation assay. 
Primary alveolar macrophages were isolated from C57BL/6 mice.  Once adhered to the 
culture dish and rested overnight, cells were stimulated with 100 ng/ml of LPS in the 
presence of serum from hepSTAT3/RelA-/- or hepSTAT3/RelA+/+ mice, uninfected or 
infected for 15 hours with 4 x 105 CFU of E. coli.  After 4 hours of stimulation, RNA was 




Figure 28. Serum components do not directly modulate ex vivo cytokine production 
in primary alveolar macrophages during LPS stimulation. 
A) Primary alveolar macrophages from C57BL/6 mice were stimulated with varying 
concentrations of LPS for 4 hours.  RNA was isolated using Trizol and IL-6 expression 
was determined using qRT-PCR.  B) Primary alveolar macrophages from C57BL/6 mice 
were stimulated with 100 ng/ml of LPS in the presence of either FBS or varying 
concentrations of serum from hepSTAT3/RelA+/+ mice infected for 15 hours with 4 x 105 
CFU of E. coli.  After 4 hours of stimulation, RNA was isolated using Trizol and IL-6 
expression was determined using qRT-PCR.  C, D) Primary alveolar macrophages from 
C57BL/6 mice were stimulated with 100 ng/ml of LPS in the presence of serum from 
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hepSTAT3/RelA-/- or hepSTAT3/RelA+/+ mice, uninfected or infected for 15 hours with 
4x105 CFU of E. coli.  After 4 hours of stimulation, RNA was isolated using Trizol and 
cytokine expression was determined using qRT-PCR.  Significance was assessed using a 
2-way ANOVA (n = 3). 	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While this assay is aimed at determining the effect of serum components on 
macrophage activation, the type of stimulation may impact the outcome, as LPS 
stimulation is TLR4 specific and may not mimic the complexities involved in an in vivo 
infection model with live E. coli.  Thus, we optimized our ex vivo system and stimulated 
primary alveolar macrophages with live E. coli (Figure 29) at varying concentrations and 
for increasing durations to determine the optimal dose and infection length at which to 
study APR-dependent changes in cytokine expression (Figure 30A, B).  High 
concentrations of E. coli, along with longer stimulation times, resulted in cell death and 
lower IL-6 expression (Figure 30A, B).  Therefore, we performed ex vivo assays using 
two different bacterial concentrations, one low (102 CFU/ml) and another high (105 
CFU/ml), for four hours to better determine if APR-dependent serum components can 
modulate macrophage cytokine production.  After stimulation with 105 CFU/ml of E. coli 
for four hours in the presence of serum from hepSTAT3/RelA-/- or hepSTAT3/RelA+/+ 
mice, uninfected or infected for 15 hours with 4 x 105 CFU of E. coli, we observed no 
changes in cytokine expression due to either genotype or infection (Figure 30C).  
Stimulation with 102 CFU/ml of E. coli resulted in low-level inductions of IL-6 and no 
induction of TNFα, suggesting that this concentration of bacteria was not an effective 
dose to stimulate macrophages ex vivo (Figure 30D).  Taken together, the data above 
suggest that APR-dependent serum components cannot directly modulate alveolar 





Figure 29. Ex vivo E. coli and serum stimulation assay. 
Primary alveolar macrophages from C57BL/6 mice were stimulated with 105 CFU/ml of 
E. coli in the presence of 1% serum from hepSTAT3/RelA-/- or hepSTAT3/RelA+/+ mice, 
uninfected or infected for 15 hours with 4 x 105 CFU of E. coli.  After 2 hours, cells were 
washed and then incubated for another 2 hours in media containing the same type of 
mouse serum.  RNA was isolated using Trizol and cytokine expression was determined 




Figure 30. Serum components do not directly modulate ex vivo cytokine production 
in primary alveolar macrophages during E. coli stimulation. 
A) Primary alveolar macrophages from C57BL/6 mice were stimulated with varying 
concentrations of log phase E. coli for 2 hours.  After 2 hours, the bacteria were washed 
off and cells were incubated for another 2 hours in complete media.  RNA was isolated 
using Trizol and IL-6 expression was determined using qRT-PCR (Duplicate values were 
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determined; n = 1).  B) Primary alveolar macrophages from C57BL/6 mice were 
stimulated with 105 CFU/ml of E. coli for varying durations.  For stimulations over 2 
hours, bacteria were washed off at 2 hours and cells were incubated for the remaining 
time in complete media.  RNA was isolated using Trizol and IL-6 expression was 
determined using qRT-PCR (Duplicate values were determined; n = 1).  C) Primary 
alveolar macrophages from C57BL/6 mice were stimulated with 105 CFU/ml of E. coli in 
the presence of 1% serum from hepSTAT3/RelA-/- or hepSTAT3/RelA+/+ mice, 
uninfected or infected for 15 hours with 4 x 105 CFU of E. coli.  After 2 hours, cells were 
washed and then incubated for another 2 hours in media containing the same type of 
mouse serum.  RNA was isolated using Trizol and cytokine expression was determined 
using qRT-PCR.  Significance was assessed by 2-way ANOVA (n = 3).  D) Primary 
alveolar macrophages from C57BL/6 mice were stimulated with 102 CFU/ml of E. coli in 
the presence of serum from hepSTAT3/RelA-/- or hepSTAT3/RelA+/+ mice, uninfected or 
infected for 15 hours with 4 x 105 CFU of E. coli.  After 2 hours, cells were washed and 
incubated for another 2 hours in media containing the same type of mouse serum.  RNA 
was isolated using Trizol and cytokine expression was determined using qRT-PCR.  




Our current results are the first, to our knowledge, to indicate a direct and 
significant influence of hepatic responses on pulmonary inflammation and host outcome 
during pneumonia. Following a higher inoculum of E. coli, hepatocyte STAT3 and RelA 
are necessary for survival, maximal bacterial clearance, and liver protection.  We have 
shown that this response, likely via RelA, is required to counter TNF-dependent toxicity 
in the liver itself.  On the other hand, our data following a milder, non-lethal inoculum 
also suggest an extra-hepatic role of the APR, whereby liver-derived products promote 
macrophage cytokine expression and innate immunity in the lungs.  
To date, there have been limited studies investigating the functional role of the 
hepatic APR during inflammation, yet most suggest an anti-inflammatory role (Renckens 
et al., 2006; Renckens et al., 2008; Sakamori et al., 2007).  Sakamori et al. showed that 
inflammatory cytokine production was amplified in hepatocyte STAT3-/- mice after 
intraperitoneal LPS injection, suggesting that STAT3-dependent APPs limit excessive 
inflammation during sepsis (Sakamori et al., 2007).  Renckens et al. demonstrated that a 
pre-existing APR reduces subsequent immune responses to pulmonary challenges with P. 
aeruginosa or A. baumannii (Renckens et al., 2006; Renckens et al., 2008).  While this is 
seemingly contradictory to the present results in which the APR supports cytokine 
synthesis and inflammation, it is notable that the models involve very different scenarios.  
Renckens et al. induced a premature APR by injection of turpentine prior to lung 
infection, whereas we interrogated the influence of hepatic responses elicited by the 
pneumonia itself.  Moreover, the APR being studied here is exclusively being induced in 
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hepatocytes downstream of STAT3 and RelA, as opposed to any and all cells responding 
to systemic turpentine administration.  Recently, our laboratory has also shown that the 
APR is necessary for survival during a Gram-positive, S. pneumoniae infection (Quinton 
et al., 2012a).  Indeed, these studies and others have now revealed over 1000 gene 
changes and numerous biological processes in the liver that are altered during 
pneumonia, any or all of which could influence disease outcome (Ahyi et al., 2013; 
Quinton et al., 2012a; Weber et al., 2012).  In those studies, hepSTAT3/RelA-/- mice 
showed decreased complement deposition and opsonophagocytosis of pneumococcus, 
leading to increased bacteremia, and suggesting that one function of the APR is to limit 
dissemination of infection.  However, those studies were not specifically empowered to 
observe effects of the APR in the lungs themselves due to the highly virulent strain of 
pneumococcus (Quinton et al., 2012a).  Using phenotypically distinct inocula of E. coli in 
our current study has enabled us to more precisely identify novel functions of the APR 
both inside and outside of the lungs during pneumonia.   
HepSTAT3/RelA+/+	  mice infected with a high dose of E. coli had a robust APR 
and high concentrations of circulating APPs, and this response was ablated in the absence 
of hepatocyte STAT3 and RelA.  Interestingly, airspace concentrations of SAA in 
hepSTAT3/RelA+/+ mice were significantly increased and reflected those in the 
circulation, but there was no change from baseline in hepSTAT3/RelA-/- mice.  There was 
also no difference in mRNA induction in whole lung homogenates between genotypes, 
suggesting that SAA in the airspaces resulted from plasma extravasation, which is also 
evident by a significant correlation between serum and BALF SAA levels.  Other APPs 
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tested (SAP, LBP, LCN2, and CRP), however, showed no changes in BALF 
concentrations between genotypes.  This is possibly due to the kinetics of circulating APP 
changes versus lung barrier integrity.  For instance, accumulation of SAP in the airspaces 
through 24 hours may solely represent equivalent extravasation in both genotypes of 
serum SAP, which remains mostly unchanged until 30 hours, a point at which injury and 
protein influx may be receding.  SAA, on the other hand, increases more rapidly in the 
circulation of hepSTAT3/RelA+/+ mice, perhaps allowing for earlier representation of this 
difference in the airspaces.  Alternatively, different APPs may have diverse abilities to 
extravasate into the lungs during infection.  There have been multiple reports about active 
uptake of various serum proteins by alveolar epithelial cells (including albumin and 
ferritin) to transport them into the alveolar space, and SAA could be another serum 
protein whose BALF concentrations are aided by such transport mechanisms (John et al., 
2001; Kim and Malik, 2003; Williams, 1984a; Williams, 1984b; Wright et al., 1987).  
While SAP expression is restricted to the liver, LBP and LCN2 are produced in the lungs 
by alveolar epithelial cells and neutrophils (Chan et al., 2009; Cowland and Borregaard, 
1997; Dentener et al., 2000; Kjeldsen et al., 2000; Klein et al., 1998), which may 
contribute to BALF concentrations.  Overall, the relationship between circulating and 
lung APP content appears to be complex and selective, with multiple factors dictating 
protein distribution.  It is important to note, however, that our model is engineered to 
specifically indicate the consequences of liver-dependent changes, and these hepatic 
changes are ultimately responsible for the observed phenotypes.  
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Following a higher inoculum of E. coli, hepatocyte STAT3 and RelA are 
necessary for liver protection. We have shown that this response, likely via RelA, is 
required to counter TNF-dependent toxicity in the liver itself.  HepSTAT3/RelA-/- mice 
infected with a severe E. coli pneumonia also had a greater mortality rate than littermate 
controls, despite equivalent lung injury and inflammation between genotypes.  It has long 
been recognized that mice with complete RelA deficiency are embryonic lethal due to 
TNFα-dependent liver injury (Alcamo et al., 2001; Beg and Baltimore, 1996; Beg et al., 
1995; Ding and Yin, 2004; Doi et al., 1999; Li et al., 1999).  There have also been reports 
linking STAT3 and liver injury in various models (Haga et al., 2003; Klein et al., 2005; 
Kovalovich et al., 2000; StreetZ et al., 2003).  In our own studies, mice lacking both 
transcription factors suffered from TNFα-dependent liver injury, likely due to 
dysregulated apoptosis that was reversed by TNFα neutralization.  However, liver 
regeneration, which has specifically been shown to rely on STAT3 (Li et al., 2002), does 
not appear to be defective in hepSTAT3/RelA-/- mice during pneumonia since Ki67 
staining was actually increased in the absence of this transcription factor (along with 
RelA).  Interestingly, liver injury was not responsible for the increase in mortality, as 
hepatoprotection via TNFα blockade was insufficient to reduce mortality in 
hepSTAT3/RelA-/- mice.  Additionally, kidney function was normal in both groups; thus, 
the cause of mortality in hepSTAT3/RelA-/- mice remains elusive.  One possibility is that 
combined changes in both local lung innate immunity and liver injury are together 
contributing to mortality, whereas neither alone is great enough to impair survival.  The 
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degree to which these outcomes and/or other manifestations in the absence of an intact 
liver response contribute to mortality during pneumonia remains to be determined.  
  Our lower inoculum infection protocol revealed that the APR promotes lung 
inflammation.  HepSTAT3/RelA-/- mice lacking the APR have a significant reduction in 
BALF total protein and cytokine concentrations.  These findings were directly associated 
with marked decreases in BALF APP concentrations, without such differences in lung 
APP mRNA.  This, along with the hepatocyte-specific nature of our mouse model, 
strongly suggests that liver APP expression is a primary determinant of their 
concentration in injured airspaces.  One curious observation to note, however, is that 
significant differences in lung APP content (15h) precede what appear to be little (SAA) 
to no (SAP) changes in blood protein.  This discrepancy between circulating and lung 
APP content could be related to the timing of the measurements, which were taken after 
15h.  Circulating APP concentrations could be significantly different between genotypes 
at earlier time points.  Alternatively, early changes in airspace APP concentrations could 
have been secondary to reduced inflammation in hepSTAT3/RelA-/- mice, such that 
reduced levels of SAA and SAP resulted from a global decrease in protein flux.  
Nonetheless, pulmonary APP content was inherently hepatocyte STAT3- and RelA-
dependent, as the presence of these two transcription factors was the only difference 
between genotypes, suggesting that liver-derived APPs are necessary for maximal lung 
inflammation. 
We aimed to identify cell types in the lungs directly targeted by acute phase 
changes in the liver by measuring cell-specific cytokine induction in airspace 
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macrophages and neutrophils, both of which represent important cytokine sources in the 
lungs (Cassatella, 1995; Mosser and Edwards, 2008; Sibille and Reynolds, 1990).  
Excitingly, we found an altered cytokine profile in airspace macrophages, but not in 
circulating monocytes or neutrophils from any site.  The macrophage mRNA changes 
were consistent with the results observed in whole lung measurements.  To more 
conclusively determine whether plasma, and hence APP, extravasation was required for 
APR-dependent cytokine synthesis in macrophages, we also measured this outcome at 
1.5 hours of infection, a time sufficient to detect increased cytokine responses but 
preceding alveolar edema.  At this early time point, macrophage responses were identical 
between genotypes, supporting the conclusion that extravasated proteins facilitate 
macrophage cytokine production in an APR-dependent manner.  Interestingly, no such 
effect was observed in circulating cells, suggesting that the reprogramming of 
macrophages by acute phase serum occurs strictly in the alveolar compartment.  The 
specific soluble mediators responsible for linking the hepatic APR to macrophage 
cytokine responses remain unknown.  Multiple APPs can bind and activate macrophages, 
including, but not limited to, SAA (Cheng et al., 2008; Niemi et al., 2011; Shah et al., 
2006), SAP (Zhang et al., 2011), LBP (Tobias et al., 1992) and CRP (Barna et al., 1984; 
Mold and Du Clos, 2006).  It is also possible that the net effect of acute phase changes is 
determined by a combination of relatively modest influences from numerous factors. 
Thus, it is possible, if not likely, that our findings cannot be traced to a single protein.  
Additionally, we show that APR-dependent serum components cannot directly modulate 
macrophage cytokine responses ex vivo.  Whether or not these results recapitulate an in 
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vivo setting, remains to be determined.  Regardless, the data provide evidence for a cell-
specific, functional role of the APR in facilitating macrophage activation during 
pneumonia.   
 Our data are the first to show that APR signals intrinsic to the liver are 
hepatoprotective, while extra-hepatic consequences of the APR are necessary to promote 
host defense and pulmonary inflammation during pneumonia.  While promoting 
inflammation can be detrimental in the context of acute lung injury, the liver response to 
pneumonia is also pro-defense, and importantly, pro-survival.  This protective nature of 
the liver is consistent with our own studies (Quinton et al., 2012a) and others’ during 
infection (Sander et al., 2010; Weber et al., 2012).  For instance, Weber et al. showed that 
liver-derived cholesterol attenuates the pathogenesis of a common streptococcus 
virulence factor, pneumolysin (Weber et al., 2012).  Sander et al. observed that hepatic 
STAT3-dependent signals (SAA in particular) could attenuate mortality during 
polymicrobial sepsis, perhaps through mobilization of myeloid derived suppressor cells 
(Sander et al., 2010).  While neither of these particular examples is likely to explain our 
own results with Gram-negative pneumonia, they importantly put forth additional 
evidence that liver function is indispensable for modulating the pathogenesis of acute 
infection.  Overall, our results indicate that APPs serve critical roles extending beyond 
their common use as biomarkers.  A better understanding of the lung-liver axis will 
provide valuable insights into potential therapeutic or diagnostic targets for clinical 




CHAPTER FOUR: ACTIVATION OF HEPATIC STAT3 MAINTAINS 
PULMONARY DEFENSE DURING ENDOTOXEMIA.  	  
Rationale 
Sepsis is a complex immunopathological syndrome defined by the systemic 
inflammatory response to infection, and is a leading contributor to morbidity and 
mortality in intensive care units as evidenced by approximately 750,000 cases per year 
(2% of all hospital admissions) (Angus et al., 2001; Angus and van der Poll, 2013; Lagu 
et al., 2012).  This multifaceted, systemic inflammatory response can be further 
complicated by organ dysfunction (severe sepsis) and hypotension (septic shock), all 
which lead to a complex, variable syndrome with mortality rates between 30 and 50% 
(Bosmann and Ward, 2013).  While pneumonia is the leading cause of sepsis, with about 
half of all sepsis cases originating as respiratory infections (Angus and van der Poll, 
2013), sepsis also greatly increases a patient’s subsequent susceptibility to bacterial 
pneumonia (Alberti et al., 2002).  In fact, 10 - 30% of mechanically ventilated, septic 
shock patients develop ventilator-associated pneumonia (Chastre and Fagon, 2002).  This 
positive association extends beyond ventilator-related circumstances, and has been 
corroborated experimentally by multiple studies demonstrating deleterious effects of 
sepsis and/or endotoxemia on pneumonia outcomes (Benjamim et al., 2010; Delano et al., 
2010; Deng et al., 2006; Frevert et al., 1994; Jung et al., 2012; Nelson et al., 1990; 
Steinhauser et al., 1999; Wagner et al., 1999; White et al., 1986). With the rapid increase 
in prevalence of drug resistant pathogens and limited treatment options available, there is 
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a growing need to develop novel pharmaceutical interventions and to elucidate our 
understanding of the inflammatory processes involved in both pathologies.   
A shared and prominent feature of sepsis, pneumonia, and other inflammatory 
conditions is the hepatic APR (Gabay and Kushner, 1999; Gamble et al., 2009; Quinton 
et al., 2009; Weber et al., 2012).  While it is well appreciated that sepsis can cause 
pulmonary immunosuppression and pneumonia susceptibility (Alberti et al., 2002; 
Benjamim et al., 2010; Delano et al., 2010; Deng et al., 2006; Frevert et al., 1994; Jung et 
al., 2012; Nelson et al., 1990; Steinhauser et al., 1999; Wagner et al., 1999; White et al., 
1986), it is unclear whether or how pre-existing liver activation (i.e. sepsis-induced APR) 
modulates subsequent responses to local lung infections.   
As detailed above, STAT3 is one of two transcription factors (along with RelA) 
required for induction of a strong hepatic APR during pneumonia (Ahyi et al., 2013; 
Hilliard et al., 2015; Quinton et al., 2012a).  In Chapter 3 (Hilliard et al., 2015), we show 
that this lung-liver axis, enabled by both transcription factors, is required for maximal 
protection during pneumonia alone, but the distinct roles of STAT3 (vs. RelA) in this 
process remain unclear.  Others have linked hepatic STAT3 activity to the APR in 
models of sepsis (Alonzi et al., 2001; Sakamori et al., 2007).  Given the close association 
between pneumonia, sepsis, STAT3, and the APR, we sought to determine the direct 






4.1 The APR is dependent on liver STAT3 during endotoxemia followed by pneumonia. 
 In order to determine the effect of STAT3-dependent liver activation in the 
context of sepsis and pneumonia, we used the Cre-LoxP system to obtain a mouse model 
of hepatocyte specific, functional STAT3 deletion (hepSTAT3-/-).  To model aspects of 
the clinical circumstances of sepsis preceding pneumonia, we employed a dual challenge 
of endotoxemia followed by a bacterial lung challenge (Figure 31).  HepSTAT3-/- and 
hepSTAT3+/+ mice were administered an i.p. injection of either 5 mg/kg of LPS or 
vehicle (saline).  After 18 hours, 1x106 CFU of E. coli, strain O6:K2:H1, was 
intratracheally instilled into left lung lobes for an additional 0, 6, or 24 hours.  As stated 
previously, Gram negative infections, including E. coli pneumonias, are a major cause of 
nosocomial pneumonia (Ahmed and Niederman, 2001; Jones, 2010), which are 
particularly relevant during sepsis as septic patients have a much greater risk of 
developing enterobacterial, hospital-acquired pneumonias (Alberti et al., 2002; Chastre 
and Fagon, 2002).  As such, E. coli pneumonia was utilized in this model for sepsis-
induced pneumonia because of its specific relevance to septic patients.  Because liver 
STAT3 activation is required for maximal APR induction (Ahyi et al., 2013; Alonzi et 
al., 2001; Quinton et al., 2012a; Sakamori et al., 2007), we measured concentrations of 
two representative, circulating APPs –SAA and SAP.  In hepSTAT3+/+ mice, serum 
concentrations of both SAA and SAP were induced dramatically above baseline with LPS 




Figure 31. The APR is dependent on liver STAT3 activation during endotoxemia 
followed by pneumonia.  
HepSTAT3+/+ and hepSTAT3-/- mice were pretreated with an intraperitoneal injection of 
5 mg/kg LPS.  After 18 hours, mice were intratracheally infected with 1x106 CFU of E. 
coli.  Mice were euthanized at 0, 6, or 24 hours post E. coli infection.  At the indicated 
time points, serum was collected, and SAA and SAP acute phase protein concentrations 
were measured using an ELISA.  Dashed lines indicate baseline concentrations in 
vehicle-treated, hepSTAT3+/+ mice without pneumonia.  *p < 0.05 for overall effect of 
genotype as determined by 2-way ANOVA.  # p < 0.05 vs hepSTAT3+/+ mice at the 
indicated time point as determined by a Holm-Sidak post hoc test (n = 3-9 per group).  
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Unlike SAA, SAP serum concentrations were further increased by E. coli infection, as 
there was a significant effect of infection only for SAP serum levels (Figure 31B).  
Independent of treatment (LPS and/or E. coli pneumonia) APP concentrations remained 
unchanged in hepSTAT3-/- mice but were significantly different from hepSTAT3+/+ mice, 
indicating that hepatic STAT3 function is necessary for a maximal APR.   
In order to determine whether an endotoxin-induced (STAT3-dependent) APR 
could affect the local lung environment, we sampled the protein and cellular content of 
the airspaces by BAL.  LPS pretreatment alone was insufficient to alter baseline 
concentrations of airspace SAA and SAP in either mouse genotype (Figure 32 – 0h).  
However, intrapulmonary infection with E. coli markedly increased concentrations of 
both APPs in the BALF of hepSTAT3+/+ mice.  SAP increases in BALF were 
significantly blunted in hepSTAT3-/- mice, with a similar trend observed for SAA (Figure 
32).  These changes resembled those in the blood compartment, suggesting that airspace 
APP content is a function of plasma extravasation into pneumonic lungs, especially in the 
case of SAP.  This is further evidenced by significant correlations between serum and 





Figure 32. During endotoxemia and pneumonia, intrapulmonary APPs are reflective 
of serum APP content. 
HepSTAT3+/+ and hepSTAT3-/- mice were pretreated with an intraperitoneal injection of 
5 mg/kg LPS.  After 18 hours, mice were intratracheally infected with 1x106 CFU of E. 
coli.  Mice were euthanized at 0, 6, or 24 hours post E. coli infection.  BALF was 
collected, and SAA and SAP concentrations were measured using an ELISA.  *p < 0.05 
for overall effect of genotype as determined by 2-way ANOVA.  # p < 0.05 vs 
hepSTAT3+/+ mice at the indicated time point as determined by a Holm-Sidak post hoc 




Figure 33. Circulating levels of APPs significantly correlate with airspace 
concentrations after endotoxemia followed by pneumonia.  
(A) SAA and (B) SAP concentrations from 24-hour serum and BALF (from Figures 27 
and 28) were compared, and a correlation with a linear regression was performed.  Each 
individual point represents a single mouse (both hepSTAT3+/+ and hepSTAT3-/-).  




4.2 Host defense during endotoxemia and pneumonia is compromised by lack of hepatic 
STAT3.	  
In order to determine if an endotoxemia-induced hepatic APR affects pulmonary 
host defense and/or inflammation during pneumonia, we measured 24-hour lung and 
blood bacterial burdens in both genotypes of mice pretreated with either LPS or vehicle.  
While antibacterial defense was equivalent in 3 of 4 groups, hepSTAT3-/- mice pretreated 
with LPS had significantly greater lung bacterial burdens (Figure 34A), suggesting that 
STAT3-dependent liver activity is required for local defense in response to a pre-existing 
endotoxemia.  HepSTAT3-/- mice pretreated with LPS also had significantly increased 
bacteremia, possibly due to differences in dissemination and/or systemic clearance 
(Figure 34B).  Interestingly, 24 hours after E. coli in endotoxemic hepSTAT3-/- mice, 
impaired antibacterial defense was associated with increased mortality (Figure 34C).  
Given the results detailed in Chapter 3 showing the necessity for hepatic STAT3 and 
RelA in pulmonary host defense during pneumonia alone (Hilliard et al., 2015), we aimed 
to determine if the hepatic APR induced by both transcription factors played a similar 
role in lung defense during sepsis-induced pneumonia as observed with single STAT3 
mutant mice.  After just 15 hours of i.p. LPS treatment, endotoxemic hepSTAT3/RelA-/- 
mice had significantly greater mortality than all other groups tested (Figure 34D).  This 
result is unsurprising given that liver RelA activation is necessary for hepatoprotection 
during pneumonia.  Intraperitoneal LPS may have caused a rapid liver response 




Figure 34. Host defense during endotoxemia and pneumonia is compromised by 
lack of hepatic STAT3. 
HepSTAT3+/+ and hepSTAT3-/- mice were treated for 18 hours with intraperitoneal LPS 
or saline followed by intratracheal E. coli.  After 24 hours of E. coli infection, (A) lungs 
were homogenized and (B) blood was processed for quantification of viable bacteria.  † p 
< 0.05 between the denoted groups based on a Kruskal-Wallis test followed by Dunn’s 
multiple comparison test (n = 5-16 per group).  C) Survival was observed through 24 
hours of infection.  A Mantel-Cox text was used to determine significance (n = 4-38 per 
group).  D) HepSTAT3/RelA-/- and hepSTAT3/RelA+/+ mice were treated with 
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intraperitoneal LPS.  Survival was observed through 18 hours.  A Mantel-Cox text was 
used to determine significance (n = 4-6 per group). 
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While future experiments are needed to confirm hepatotoxicity as the cause of mortality 
in APR-null, hepSTAT3/RelA-/- mice, this finding was sufficient to preclude the efficacy 
of this mouse model for studies employing endotoxemia prior to pneumonia.  
Bacterial killing in the lungs relies on innate immunity, including that provided by 
recruited neutrophils and other extravasated plasma constituents during inflammation 
(Quinton and Mizgerd, 2015).  In order to determine whether local inflammation was 
compromised by STAT3 deficiency, we measured BALF neutrophil recruitment and total 
protein concentrations (Figure 35A, B).  We observed an influx of neutrophils at 24 hours 
post E. coli in both hepSTAT3+/+ and hepSTAT3-/- mice, consistent with an acute 
pneumonia (Figure 35A).  Additionally, there were significantly greater numbers of 
neutrophils recruited to the airspaces in hepSTAT3-/- mice compared to hepSTAT3+/+ 
mice at 24 hours post E. coli, which was likely secondary to increased bacterial loads.  
BALF total protein concentrations were also increased due to infection, but no 
differences were observed between genotypes (Figure 35B).  These data suggest that 
STAT3-dependent liver responses are protective in the setting of sepsis followed by 
pneumonia. This response, however, does not appear to be mediated through alveolar 





Figure 35. Neutrophil recruitment is not dependent on hepatic STAT3 activation 
during endotoxemia followed by pneumonia. 
HepSTAT3+/+ and hepSTAT3-/- mice were treated for 18 hours with intraperitoneal LPS 
followed by intratracheal E. coli.  At the indicated time points, BALF was harvested for 
determination of (A) recruited neutrophils numbers and (B) total protein concentrations.  
* p < 0.05 vs hepSTAT3+/+ mice at the indicated time point as determined by a two-way 
ANOVA followed by a Holm-Sidak test (n = 3-9 per group). ND = not detected.  
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4.3 Pulmonary and systemic cytokine induction is not reliant on STAT3-dependent acute 
phase changes. 
As another index of lung and systemic inflammation, BALF and serum cytokine 
protein concentrations were measured (Figures 36 and 37).  We utilized a multiplex bead 
array to determine concentrations of 10 cytokines, all of which are relevant to pneumonia 
and/or lung injury (Quinton and Mizgerd, 2011; Quinton and Mizgerd, 2015) — IL-1β, 
IL-6, IL-10, IL-17, G-CSF, GM-CSF, CXCL1, TNFα, LIF, and CXCL2.  We observed 
several patterns of cytokine kinetics in the airspaces, ranging from increases due to E. 
coli infection to no change at all, but there were no changes in BALF cytokine 
concentrations due to genotype (Figure 36).  Serum cytokine changes were also variable 
across targets, however, unlike in the BALF, three serum cytokines were significantly 
changed due to the absence of liver STAT3 —IL-1β, IL-17 and TNFα (Figure 37).  
Concentrations of both IL-17 and TNFα were significantly greater in hepSTAT3-/- mice, 
consistent with increased bacteremia.  Interestingly, IL-1β was significantly decreased in 
hepSTAT3-/- mice after LPS pretreatment (0h post-E. coli), but not during the course of 
infection, potentially indicating a small defect in systemic innate immunity.  Whether or 
how this genotype-dependent decrease in IL-1β contributes to the phenotype of this 




Figure 36. Pulmonary cytokine induction is unaffected by hepatic STAT3 deletion. 
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HepSTAT3+/+ and hepSTAT3-/- mice were treated for 18 hours with intraperitoneal LPS 
followed by intratracheal E. coli.  At the indicated time points after E. coli infection, 
lungs were lavaged and BALF cytokine protein concentrations were determined using a 
multiplex bead array.  Dashed lines (some of which overlap with the X-axis) indicate 
baseline concentrations in vehicle-treated, hepSTAT3+/+ mice without pneumonia.  There 
was no significant overall effect of genotype observed.  Significance was assessed using a 








HepSTAT3+/+ and hepSTAT3-/- mice were treated for 18 hours with intraperitoneal LPS 
followed by intratracheal E. coli.  At the indicated time points after E. coli infection, 
serum was collected and cytokine concentrations were measured with a multiplex bead 
array.  Dashed lines (some of which overlap with the X-axis) indicate baseline 
concentrations in vehicle-treated, hepSTAT3+/+ mice without pneumonia.  For IL-1ß, *p 
< 0.05 vs. hepSTAT3+/+ mice at that time point as determined by a two-way ANOVA 
followed by a Holm-Sidak test.  For IL-17 and TNFα *p < 0.05 for overall affect of 
genotype as determined by two-way ANOVA.  n = 3-9 per group. 
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4.4 The hepatic APR does not modulate phagocytosis in airspace cells during 
endotoxemia and pneumonia. 
Hepatic STAT3-/- mice with a pre-existent endotoxemia have increased bacterial 
burdens both systemically and locally during pneumonia.  Neutrophil recruitment and 
other inflammatory mediators (i.e. cytokines) were either unchanged or increased in 
hepSTAT3-/- mice, suggesting that these aspects of host defense are uncompromised in 
hepSTAT3-/- mice.  To determine if endotoxin-induced liver STAT3 activation affects 
cellular defenses during pneumonia, we measured phagocytosis in airspace macrophages 
and neutrophils using pHrodo E. coli bioparticles.  These bioparticles are conjugated to a 
phycoerythrin (PE) fluorophore that fluoresces only in low pH environments, 
characteristic of the phagolysosomal compartment.  This system has been validated by 
multiple laboratories as an effective strategy for discriminating between surface bound 
and internalized particles (Berger et al., 2010; Deriy et al., 2009; Neaga et al., 2013).  
After 18 hours of intraperitoneal LPS, hepSTAT3-/- and hepSTAT3+/+ mice were i.t. 
infected with E. coli for 6 hours followed by a second i.t. instillation with pHrodo E. coli 
bioparticles.  After one hour, the lungs were lavaged and cells were analyzed by flow 
cytometry (Figure 38).  Airspace macrophages and neutrophils included cells positive for 
phagocytosis of pHrodo bioparticles (Figure 38A).  Neither macrophages nor neutrophils 
in the airspaces, however, exhibited genotype-dependent differences in the frequency 




Figure 38. The hepatic APR does not modulate phagocytosis in airspace cells during 
endotoxemia and pneumonia. 
HepSTAT3+/+ and hepSTAT3-/- mice were treated with intraperitoneal LPS for 18 hours.  
Afterwards, E. coli was instilled intratracheally, followed six-hours later by a second 
instillation of E. coli pHrodo particles.  Lungs were lavaged an hour later and cells were 
stained as follows for flow cytometry: neutrophils (CD45+/7AAD-/Ly6G+/F4/80-) and 
alveolar macrophages (CD45+/7AAD-/F4/80+/Ly6G-/Autofluorescencehi).  A) 
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Representative histograms illustrate the percentages of cells positive for pHrodo particle 
phagocytosis in hepSTAT3+/+ (black line) and hepSTAT3-/- (dashed line) mice.  Filled 
curves (gray) represent cells not exposed to pHrodo particles.  Summarized data for all 
mice studied were calculated to determine the (B) frequency and (C) magnitude of 
particle ingestion, as determined by the percentage of positive cells and mean 
fluorescence intensity, respectively.  No significant changes between genotypes were 
detected, as assessed by a student’s t test (n = 5-6 per group). 
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These data suggest that bacterial uptake and phagolysosomal fusion are unlikely to be 
responsible for impaired bacterial killing in the absence of hepatocyte STAT3 during 
endotoxemia and pneumonia. 
 
4.5 Maximal ROS generation in airspace macrophages is dependent on hepatic STAT3 
activation. 
As an alternative contributor to cellular host defense, ROS generation was 
measured in airspace cells from both genotypes following 6 hours of pneumonia in 
endotoxemic mice.  Total cells were stained for surface antigens to identify macrophages 
and neutrophils as described above, and ROS production was measured using the 
CellROX Deep Red Reagent from Life Technologies (Figure 39A).  Interestingly, 
airspace macrophages from hepSTAT3-/- mice had significantly less ROS production than 
those from hepSTAT3+/+ mice (Figure 39B).  A similar trend was apparent with 
neutrophils, but this did not reach statistical significance (Figure 39B).  These data 
connect compromised macrophage ROS production to impaired pulmonary host defense 





Figure 39. Alveolar macrophage ROS production is dependent on hepatic STAT3 
activation. 
HepSTAT3+/+ and hepSTAT3-/- mice were treated for 18 hours with intraperitoneal LPS 
followed by an intratracheal instillation of E. coli.  6 hours later, the lungs were lavaged 
and recovered cells were stained using the CellROX Deep Red Reagent to determine 
ROS generation in neutrophils (CD45+/7AAD-/Ly6G+/F4/80-) and alveolar macrophages 
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(CD45+/7AAD-/F4/80+/Ly6G-/Autofluorescencehi).  A) Representative histograms 
illustrate the mean fluorescence intensity (MFI) for the populations positive for ROS 
generation in hepSTAT3+/+ (black line) and hepSTAT3-/- (dashed line) mice.  Filled 
curves (gray) represent cells not exposed to CellROX Reagent.  B) ROS generation was 
quantified in each cell type and data are illustrated as the percentage of ROS generation 
observed in hepSTAT3+/+ mice.  § p < 0.05 vs hepSTAT3+/+ as determined by a student’s 
t test (n = 5-6 per group).  
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4.6 Soluble host defense mediators within the airspaces are dependent on the hepatic 
APR. 
 Neutrophils are immediately recruited to the alveolar compartment during early 
stages of infection to aid in pathogen clearance (Mizgerd, 2008).  As an innate defense, in 
addition to phagocytosis, neutrophils are equipped to release endogenous genomic DNA 
laced with antimicrobial proteins to effectively trap and lyse invading microbes.  These 
NETs are studded with granulocytic proteins, including MPO (Brinkmann and 
Zychlinsky, 2012).  As a way to determine whether NET release is affected by the APR, 
we measured relative concentrations of NETs in BALF from hepSTAT3+/+ and 
hepSTAT3-/- mice after endotoxemia and pneumonia using a previously described MPO-
DNA ELISA (Figure 40A) (Caudrillier et al., 2012).  As anticipated, we observed an 
overall increase in NET release due to pneumonia, and while there is a trend towards 
decreased NET release in hepSTAT3-/- mice, this difference did not reach statistical 




Figure 40. Neutrophil extracellular trap release is unchanged in BALF from 
hepSTAT3-/- mice during endotoxemia and pneumonia. 
A) NETs in the BALF were quantified by a MPO-DNA ELISA.  Briefly, a 96-well plate 
coated with an anti-MPO capture antibody was incubated with the BALF.  MPO-DNA 
complexes (indicative of NETs) bound to the anti-MPO capture antibody were detected 
using a peroxidase-labeled anti-DNA detection antibody.  B) BALF was collected from 
hepSTAT3+/+ and hepSTAT3-/- mice pretreated with LPS for 18 hours followed by 
intrapulmonary infection with E. coli for the indicated time periods, and NETs were 
quantified using the MPO-DNA ELISA as described above.  Significance was assessed 
by a two-way ANOVA followed by a Holm-Sidak test (n = 3-9 per group).   
	  	  
134	  
In order to determine whether extracellular products other than NETs may 
contribute to differential bacterial resistance in the alveolar lining fluid, we developed an 
assay in which we incubated luminescent E. coli (strain Xen14) in cell- and bacteria-free 
BALF from endotoxemic and pneumonic hepSTAT3+/+ or hepSTAT3-/- mice (Figure 
41A).  Bacterial growth was calculated as fold increases in luminescence compared to the 
starting values for each sample.  Interestingly, BALF from hepSTAT3-/- mice supported 
bacterial growth significantly more than that from hepSTAT3+/+ mice (Figure 41B), 
suggesting that the airspace milieu of hepSTAT3-/- mice is less resistant to bacterial 
growth.  Whether and how this change in bacterial resistance in the airspaces relies on 





Figure 41. Ex vivo bacterial growth assay 
A) BALF was collected from hepSTAT3+/+ and hepSTAT3-/- mice pretreated with LPS 
for 18 hours followed by intrapulmonary infection with E. coli for the indicated time 
periods. The cell- and bacteria-free BALF was incubated with log-phase, luminescent E. 
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coli, rotating at 37°C for five hours.  Luminescence, as a function of bacterial growth, 
was measured using a luminometer.  B) Bacterial growth was calculated as fold increases 
in luminescence compared to the starting values for each sample. * p < 0.05 vs 
hepSTAT3+/+ at the specified time point as assessed by two-way ANOVA followed by a 




The results of this study demonstrate a novel role for the STAT3-dependent liver 
acute phase response in driving innate host defenses during pneumonia in endotoxemic 
animals.  Using a two-hit model of endotoxemia and intrapulmonary E. coli, we observed 
impaired antibacterial defense and higher mortality in mice that were deficient in hepatic 
STAT3.  While several indices of inflammation (e.g. neutrophilia, edema, and cytokine 
induction) were largely unaffected by interruption of hepatic activation, others (e.g. 
macrophage ROS generation and airway lining fluid content) were dependent on hepatic 
STAT3.   
 Physiologic and molecular mechanisms by which hepatic innate responses 
mediate host defense during sepsis and pneumonia have never been elucidated.  Several 
studies, however, have implicated important roles for hepatic STAT3 activation during 
either sepsis or pneumonia alone.  Alonzi et al. described the necessity of STAT3 
activation during endotoxemia for induction of the APR (Alonzi et al., 2001).  
Additionally, Sakamori et al. used a hepatocyte-specific STAT3 knockout mouse to show 
the importance of this signaling pathway in controlling excessive inflammation during 
polymicrobial sepsis induced by CLP (Sakamori et al., 2007).  In fact, their results in 
mutant mice during sepsis alone were consistent with our own, with decreased survival, 
as well as increases in circulating cytokines; although, they did not detect changes in 
blood bacterial burdens.  Similarly, Sander et al. demonstrated that liver STAT3-
dependent signaling was crucial to attenuate mortality, but not host defense, in response 
to CLP through a process facilitated by SAA-dependent mobilization of myeloid-derived 
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suppressor cells (Sander et al., 2010).  The latter two studies described above, while 
notable, were not designed to determine the degree to which sepsis-induced liver 
activation (via STAT3) calibrates subsequent responses to pneumonia, which is a highly 
distinct and clinically relevant scenario.  
It is well established that in both septic patients and animal models, sepsis results 
in immunosuppression (Reddy et al., 2001b), which is thought to promote secondary 
infections such as those causing pneumonia (Delano et al., 2010; Hotchkiss et al., 2013).  
A multitude of studies have revealed detrimental consequences of sepsis-induced 
immunosuppression on critical pneumonia outcomes, including antibacterial defense, 
alveolar macrophage function, alveolar neutrophil recruitment, and cytokine production 
(Benjamim et al., 2010; Carrick et al., 1997; Chen et al., 2000; Frevert et al., 1994; Jung 
et al., 2012; Nelson et al., 1990; Reddy et al., 2001a; Song et al., 2014; Steinhauser et al., 
1999; Wagner et al., 1999; Wagner et al., 2002; White et al., 1986).  Our own protocol of 
endotoxemia followed by pneumonia, however, was not sufficient to recapitulate the 
circumstances of sepsis-induced immunosuppression.  We observed no effect of 
endotoxemia alone on pulmonary defense in hepSTAT3+/+ mice, but rather, endotoxemia 
compromised bacterial clearance only in mice lacking hepatic STAT3.  There are many 
possible explanations for this.  First, the dose of LPS (5 mg/kg) and/or its type (an 
ultrapure, TLR4 agonist) may not be sufficient to induce immunosuppression in the 
setting of our pneumonia protocol.  Additionally, the timing of LPS pretreatment (18 
hours before E. coli infection) and/or the genetic background of our hepSTAT3-/- mouse 
strain could also be factors.  The lack of observable LPS-induced immunosuppression in 
	  	  
139	  
hepSTAT3+/+ mice, however, empowered us to more precisely examine the roles of 
endotoxin-induced hepatic STAT3 activation on a subsequent lung infection, and this 
opportunity may have been diminished by overwhelming immunosuppression due to LPS 
alone.  
Independently, our laboratory and others have reported a functional role for the 
APR in pneumonia alone.  We have shown, using an APR-null mouse model (lacking 
both hepatic STAT3 and RelA), that liver activation is required for survival, 
hepatoprotection, and maximal pulmonary inflammation during an E. coli pneumonia 
(detailed in Chapter 3), as well as systemic defense and opsonophagocytosis during 
pneumococcal pneumonia (Quinton et al., 2012a).  The common clinical observation that 
sepsis is frequently followed by pneumonia (Alberti et al., 2002; Chastre and Fagon, 
2002; Delano et al., 2010) raises the question of whether or how a pre-existing liver 
response alters pneumonia susceptibility, for better or for worse.  Renckens et al. 
determined that a preexisting APR induced by turpentine impairs the pulmonary 
inflammatory response to P. aeruginosa and A. baumannii (Renckens et al., 2006; 
Renckens et al., 2008).  The model of inducing a preexisting APR via turpentine injection 
is very different from our method of inducing the APR through endotoxemia.  
Additionally, turpentine’s effects are unlikely to be limited to liver activation.  Using our 
hepatocyte-specific STAT3-null mouse in our model of endotoxemia followed by 
pneumonia allowed us, for the first time, to interrogate the role of pre-existing liver-
specific acute phase changes on pneumonia susceptibility.   
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 In association with impaired APP induction, hepSTAT3-/- mice pretreated with 
LPS had significantly greater bacterial loads in the lungs and blood during pneumonia, 
implying that in the absence of an intact liver response, local pulmonary defenses are 
particularly affected during endotoxemia.  Increased mortality was also observed in this 
group, suggesting this defect in host defense as a potential cause of mortality.  These 
outcomes were also associated with an increase in serum TNFα that is likely due to 
greater amounts of circulating bacteria and could also contribute to death in hepSTAT3-/- 
mice, as TNFα can cause septic shock (Tracey et al., 1987).  In trying to determine which 
aspects of host defense are mediated by the sepsis-induced APR, we measured pulmonary 
inflammation and injury.  We observed no decrease in neutrophil recruitment, pulmonary 
cytokine concentrations, or proteinaceous edema between genotypes, suggesting that 
these characteristic measures of inflammation were unlikely to contribute to host defense 
differences in endotoxemic hepSTAT3-/- mice.  Moreover, phagocytosis and NET 
production were also equivalent between groups.  Regarding the former, however, we 
acknowledge the fact that pHrodo E. coli bioparticles (our method of quantifying 
phagocytosis) may not perfectly replicate interactions between living E. coli and the 
inflammatory milieu (including opsonins such as extravasated APPs).  Yet, we observed 
extremely efficient uptake using this system (around 40-60%) in both cell types analyzed, 
supporting a sufficient environment for comparing phagocytic function.  Interestingly, 
ROS generation was significantly attenuated in alveolar macrophages from hepSTAT3-/- 
mice, suggesting that the endotoxemia-induced hepatic APR facilitates at least one 
fundamental aspect of cell-mediated antimicrobial defense.  Results from the previous 
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chapter have implicated the APR in activation of airspace macrophages during 
pneumonia and a multitude of APPs have been shown to activate macrophages (Cheng et 
al., 2008; Mold and Du Clos, 2006; Tobias et al., 1992; Zhang et al., 2011).   
We also assessed the capacity of alveolar lining fluid to influence bacterial growth 
after endotoxemia in mice with and without STAT3-dependent liver responses.  Indeed, 
the composition of soluble mediators in this niche could have large implications on 
pathogen resistance at the air-liquid interface.  In an effort to understand whether the 
balance of growth-promoting and growth-inhibiting soluble factors were dependent on 
the APR, we incubated luminescent E. coli with cell- and bacteria-free BALF from 
hepSTAT3-/- and hepSTAT3+/+ mice collected at different time points following 
endotoxemia and E. coli infection.  Interestingly, BALF from hepSTAT3-/- mice 
supported E. coli growth significantly more than that from hepSTAT3+/+ mice, suggesting 
that products downstream of hepatic STAT3 activation create a less favorable 
environment for infection in the airspaces.  There have been multiple reports of 
antimicrobial polypeptides, including lactoferrin, lysozyme, lipocalins and beta-
defensins, which are produced in the liver and/or lungs (Bachman et al., 2011; Chan et 
al., 2009; Ganz, 2002; Li et al., 2014) and could be modulated by the APR either directly 
or indirectly.  Alternatively, increased growth in the BALF from hepSTAT3-/- mice could 
be attributable to an altered nutrient pool that is more supportive of bacterial growth.  
While our assay does not allow us to discriminate between the bactericidal and 
bacteriostatic components of BALF, this finding, combined with the defect in 
macrophage ROS generation and increased bacterial burdens strongly support the concept 
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that the sepsis-induced hepatic APR is a required component for maintaining pulmonary 
defense.  Future insight into the mechanisms by which sepsis-mediated liver activation is 
protective during subsequent lung infections will provide valuable, alternative avenues 




CHAPTER FIVE: CONCLUDING REMARKS 
Summary of Results 
 As a classical response, the APR has been employed as a biomarker for a number 
of diseases (Abernethy and Avery, 1941; Armstrong, 2006; Beard et al., 2006; de Torre et 
al., 2006; Le, 2005; MaCleod and Avery, 1941; McCarty, 1947; Sakr et al., 2008; Urieli-
Shoval et al., 2000; Verwey et al., 2008).  As discussed above, each APP has its own 
individual function, ranging from opsonization to anti-proteases activity and coagulation 
mediators (Gabay and Kushner, 1999; Suffredini et al., 1999), yet their collective 
function, especially during lung infections, has yet to be elucidated.  Previous work from 
our laboratory has shown the necessity of critical pulmonary host defense cytokines to 
activate key hepatocyte transcription factors, STAT3 and NF-κB RelA, to induce this 
response (Quinton et al., 2009), suggesting that its induction during pneumonia plays an 
important, biological role.   
Using our mouse model of APR deficiency, we show, that the APR functions to 
facilitate survival, pulmonary bacterial clearance, and hepatoprotection during a high 
inoculum E. coli pneumonia.  Infection with a lower inoculum revealed that pulmonary 
cytokine expression was also mediated by the APR.  This effect on cytokine production 
was orchestrated largely through airspaces macrophages, as neither circulating cells 
(monocytes and neutrophils) nor airspace neutrophils had differences in cytokine 
induction due to APR deficiency.  This function of the APR during pneumonia was 
further evidenced by work previously published by our laboratory (Quinton et al., 2012a), 
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which in accordance with the results detailed in this dissertation, showed the necessity of 
the APR for survival and systemic host defense during pneumococcal pneumonia.   
Not only does the hepatic APR play a functional role during pneumonia, but 
systemic STAT3-dependent liver activation also appears to modulate subsequent 
responses to pneumonia.  After our two-hit model of endotoxemia followed by bacterial 
lung infection, we observed greater pulmonary bacterial burdens in endotoxemic 
hepSTAT3-/- mice, suggesting a functional role of liver STAT3-dependent acute phase 
changes in maintaining pulmonary defense during endotoxemia.  Specifically, 
macrophage ROS generation and resistance of alveolar lining fluid to bacterial growth 
were compromised after endotoxemia in hepSTAT3-/- mice, implicating that both cellular 
and humoral defenses are reliant on liver STAT3-dependent acute phase activity.  Taken 
together, our results suggest that pulmonary and hepatic responses are connected via a 
“lung-liver axis,” which protects the host through multiple mechanisms.  Importantly, our 
findings support that the hepatic APR functions in a biologically relevant manner that far 
exceeds its usefulness as a biomarker.  
 
Putting it all together: The role of sentinel cells within the lungs 
While this dissertation is comprised of two results chapters investigating the role 
of the APR in two different yet clinically relevant scenarios, the overarching role of the 
hepatic APR is becoming increasingly clear.  Both pneumonia and sepsis are 
inflammatory conditions by nature and have similar inflammatory pathologies.  Thus it is 
unsurprising that the functions of the APR are similar in both pneumonia alone and 
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pneumonia preceded by sepsis.  Interestingly, a maximal hepatic APR was necessary for 
survival of both insults and pulmonary host defense is compromised in its absence.  
While it may seem that there are unique functions of the APR during pneumonia alone 
(e.g. induction of airspace macrophage cytokine production) or endotoxemia followed by 
pneumonia (e.g. macrophage ROS production and alveolar bacterial resistance), these 
findings appear to revolve around a central participant—the alveolar macrophage.  
Evidence from both pneumonia and endotoxemia followed by pneumonia suggest that the 
function of this key sentinel airspace cell is strongly dependent on liver activation (Figure 
42).  This is consistent with the ability of alveolar macrophages to coordinate 
inflammatory responses, even after an extra-pulmonary insult (Aggarwal et al., 2014; 
Eddens and Kolls, 2012; Hussell and Bell, 2014; Mizgerd, 2008; van der Poll and Opal, 
2008; Werner and Steele, 2014).  Future lines of investigation include understanding the 
extent of the APR’s ability to modulate macrophage functions, and the mechanism by 




Figure 42. Model: The hepatic APR induced during pulmonary inflammation 
maintains pulmonary host defense and augments alveolar macrophage activation. 
Pulmonary inflammation caused by pneumonia alone or in the context of endotoxemia 
activates hepatic STAT3 and RelA to induce the APR, leading to production of 
circulating APPs.  Circulating APPs gain access to the airspaces by way of the injured 




Long-term effects of the APR and pneumonia susceptibility 
 This study characterizes the role of the hepatic APR during an acute pneumonia, 
with outcomes measured no longer than 48 hours post infection.  Various APPs are used 
as biomarkers and prognostic indicators for a number of chronic diseases, including 
arthritis and atherosclerosis (Liuzzo et al., 1994; Mallya et al., 1982; Plant et al., 2000; 
Yudkin et al., 1999).  These chronic inflammatory conditions are associated with 
increases in circulating APP concentrations (Chambers et al., 1983; Cunnane et al., 2000; 
Liuzzo et al., 1994; Mallya et al., 1982; Yudkin et al., 1999).  The effect of these 
increases over long periods of time has yet to be examined in any setting, but our work 
here can point us in the right path in understanding the long-term effects of the APR 
during chronic inflammatory diseases.  For instance, it is possible that repeated exposure 
of myeloid cells to APPs could potentially induce tolerance of these cells to immune 
activation perhaps making patients more susceptible to secondary infections.  More likely 
however (and more supported by our data) is that a long-term increase in circulating APP 
concentrations actually protects the host, balancing the deleterious effects of the chronic 
inflammation itself.  For example, rheumatoid arthritis increases patients’ risk for 
secondary infections, like pneumonia, as well as increase APP levels, while the induced 
APR is necessary to promote survival and host defense during pneumonia (Doran et al., 
2002).  In this scenario, the APR can potentially act as a balance, protecting patients with 
chronic diseases from developing pneumonia.  Specific studies, however, need to be 
performed to understand the functions of the APR in long-term, chronic, inflammatory 





 Our results implicate the lung-liver axis in facilitating host defense and survival 
during E. coli pneumonia and endotoxemia followed by E. coli pneumonia.  While E. coli 
is an etiology of pneumonia that is clinically relevant, our specific work outlined here 
does not expand to other bacterial or viral causes of pneumonia and sepsis-induced 
pneumonia.  Our laboratory has previously published evidence that the APR has 
important functions during a Gram-positive, pneumococcal pneumonia to facilitate 
survival and prevent invasive disease (Quinton et al., 2012a).  This observation could 
certainly extend to other types of pneumonia and/or systemic infections.  In fact, multiple 
APPs and the APR as a whole have been implicated in antibacterial defenses in response 
to a variety of pulmonary and systemic insults, including S. pneumoniae, K. pneumoniae, 
P. aeruginosa, S. aureus, E. coli, A. baumannii, S. pyogenes, and LPS (Ahyi et al., 2013; 
Alonzi et al., 2001; Bachman et al., 2011; Branger, 2004; Chan et al., 2009; Hamann et 
al., 2005; Klein et al., 2007; Lamping et al., 1998; Mold and Du Clos, 2006; Noursadeghi 
et al., 2002; Quinton et al., 2012a; Quinton et al., 2009; Renckens et al., 2006; Renckens 
et al., 2008; Sakamori et al., 2007; Sander et al., 2010; Shah et al., 2006; Vernooy et al., 
2005; Yuste et al., 2007).  These studies put forth multiple lines of evidence that bring the 
APR to the center of multiple inflammatory conditions, like pneumonia and sepsis, and 
link them through a common hepatic response.  These studies, and our work with two 
different incoulums of E. coli also suggest that the magnitude of the response is 
dependent on the dose and pathogen.  Organisms less likely to mount an immune 
response (for their own benefit) would be less likely to induce the hepatic APR, as the 
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APR is stimulated by the immune response itself and not directly by the pathogen.  Our 
own studies, however, are the first to show a functional role for the hepatic APR as a 
whole (not just individual APPs) induced by the inflammatory response in facilitating 
survival and maintaining pulmonary host defense in multiple contexts of E. coli 
pneumonia.  Future studies, however, are necessary to determine the holistic role of the 
APR in other types of inflammatory conditions.   
 The efficacy of mouse models has recently been debated, especially their 
usefulness in understanding various inflammatory conditions.  It has long been 
understood that mice can tolerate greater quantities of endotoxin that humans.  In fact, 
mice require 250 times more endotoxin than humans to cause the same level of 
inflammation (Copeland et al., 2005).  Copeland et al. also show that while this response 
must be stimulated by a much greater insult, it is very similar to that induced in humans 
(Copeland et al., 2005).  Additionally other groups have reported on the usefulness of 
mouse models.  Two reports, published back to back, used the same data set to come to 
opposite conclusions about the similarity of the inflammatory response in mice and 
humans (Seok et al., 2013; Takao and Miyakawa, 2015).  By comparing the 
transcriptional response of total blood leukocytes to trauma, burn, or endotoxin in 
humans and mice, Seok, et al. concluded that mouse models poorly mimicked human 
patients of the same condition, whereas Takao et al. determined the opposite (Seok et al., 
2013; Takao and Miyakawa, 2015).  Disparate results could be a result of the differential 
white blood counts in mice and humans. Moreover, human patients received hospital 
supportive care, while mice did not.  Therefore, it is unsurprising that comparing the 
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responses of different cells, under different circumstances would lead to disparate 
conclusions.  By utilizing our novel APR-null mouse model, we are able to specifically 
determine the necessity of hepatic STAT3 and RelA during lung infections, something 
that could not have been done with cell culture or patient samples alone.  Additionally, by 
providing a better understanding of a conserved response that is already utilized as a 
biomarker in humans, we will be better able to develop therapeutics that modulate the 
hepatic APR to treat patients with or at risk for pneumonia and other inflammatory 
conditions.   
 
Future Directions 
 Our studies revealed a crucial role for the APR in maintaining pulmonary host 
defense and inflammation via alveolar macrophages during pneumonia.  Future directions 
should focus on specifically how the ARP does this and whether it is through direct or 
indirect mechanisms.  Our ex vivo serum stimulation assays suggest that serum 
components themselves cannot directly modulate macrophage activation.  Negative data, 
however is hard to interpret, as the experimental design could be hampering our ability to 
see APR-dependent changes in macrophage cytokine production ex vivo.  Other studies, 
including microarrays on macrophage RNA from uninfected or infected APR-null or 
control mice would reveal genome wide, APR-dependent changes that could indicate 
specific signaling pathways or receptors involved.  Additionally, in vivo gain of function 
studies in which serum from hepSTAT3/RelA+/+ mice is instilled into APR-null, 
hepSTAT3/RelA-/- mice during a low inoculum pneumonia to rescue pulmonary 
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inflammation would again indicate whether APR-dependent serum components can 
directly influence macrophage activation.  It is important to note, however, that the role 
of the APR in pulmonary inflammation and host defense is most likely not attributable to 
just one APP, but rather is likely a combined effect of a multitude of APPs.  Thus, 
narrowing down the direct mechanism may be difficult. 
 While our findings point to macrophages in regulating the APR-dependent 
inflammatory response, we have not determined if other cell types, namely alveolar 
epithelial cells, are modulated by the APR as well.  Our lab has developed a novel lung 
digest protocol to isolate intact alveolar epithelial cells from infected lungs.  Using this 
protocol, we can determine if the APR facilitates pulmonary inflammation and host 
defense through alveolar epithelial cells in addition to macrophages.  These cells have 
recently gained more notoriety in having specific antibacterial and immune stimulating 
functions separate from their classic role as barrier cells (Mizgerd, 2008; Quinton and 
Mizgerd, 2011; Quinton and Mizgerd, 2015), and are the first cells to encounter exudate 
APPs as they enter the injured lungs; thus it would be unsurprising if they were involved. 
 As described earlier, many APPs are mediators of the coagulation cascade, an 
important pathway in promoting both resolution and repair in the lungs after an acute 
pneumonia.  Future studies should include those to determine the role of the hepatic APR 
in this process.  While differences in survival with an E. coli pneumonia may make this 
difficult, other model organisms or agonists could be particularly helpful.  Intratracheal 
administration of LPS is used as a classic inducer of acute lung injury, resulting in a 
robust repair process (Mizgerd and Skerrett, 2008).  Additionally, LPS is a sterile insult, 
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thus removing the confounding effect of any potential host defense differences in our 
APR-null mouse model.  Understanding how and if the hepatic APR modulates this 
process can reveal yet another functional role of the APR during pneumonia and further 
help patients with or at risk for pneumonia. 
 
Clinical Implications 
Treatments for both sepsis and pneumonia are severely limited and are generally 
reliant on antibiotic therapy and supportive care.  Unfortunately, antibiotic resistant 
infections, including both pneumonia and sepsis, are becoming more prevalent (van der 
Poll and Opal, 2009).  Because of this, the need for traditional antibacterial compounds 
has decreased, while the necessity of novel immunomodulators has greatened.  As such, 
we have shown that the liver-derived APR modulates the immune response in two very 
important clinical scenarios.  Additionally, the liver is an easily targetable organ because 
of its highly vascularized nature (Bhadra et al., 2005; Mishra et al., 2013; Wang et al., 
2014), and the APR could be easily regulated with different small molecule agonists and 
antagonist for STAT3 and/or RelA, some of which are already undergoing the patenting 
process (Yu et al., 2013).  As observed in both experimental scenarios tested, the APR 
was effective in controlling bacterial outgrowth, without compromising tissue integrity, 
thus the potential for boosting host defense, without contributing to antibacterial 
resistance is evident.  More work needs to be done, however, to determine the efficacy of 
such exogenous manipulation.   
	  	  
153	  
Additionally, this work will expand the usefulness of the hepatic APR as a 
prognostic or diagnostic tool during a multitude of inflammatory disorders.  Both 
pneumonia and sepsis are heterogeneous conditions that affect a multitude of patients 
with various pre-existing conditions and backgrounds.  Moreover, differences in infection 
etiologies only complicate patient stratifications more.  Hepatic APR activation occurs in 
response to a variety of different pathogens, including both Gram negative and positive 
infections, and is modulated based on the severity of infection.  Thus, liver activation 
status can help to stratify patients and delineate subgroups, which are better suited to 
respond to certain drugs or treatments than other therapeutics.  A better understanding of 
the causal link between the APR as a biomarker and its role in the outcome of disease 
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